

1 Rebecca Peterson-Fisher (SBN 255359)  
2 Jennifer L. Liu (SBN 279370)  
3 C. Leah Kennedy (SBN 346306)  
4 **LIU PETERSON-FISHER LLP**  
5 1204 Burlingame Ave., Suite 3  
6 Burlingame, CA 94010  
7 Tel: 650.461.9000  
8 Fax: 650.460.6967  
9 Email: rpf@liupetersonfisher.com  
10 jliu@liupetersonfisher.com  
11 lkennedy@liupetersonfisher.com

8 Barbara J. Chisholm (SBN 224656)  
9 Danielle E. Leonard (SBN 208201)  
10 Connie K. Chan (SBN 284230)  
11 Robin S. Tholin (SBN 344845)  
12 **ALTSHULER BERZON LLP**  
13 177 Post Street, Suite 300  
14 San Francisco, CA 94108  
15 Tel: 415.421.7151  
16 Fax: 415.362.8064  
17 E-mail: bchisholm@altshulerberzon.com  
18 dleonard@altshulerberzon.com  
19 cchan@altshulerberzon.com  
20 rtholin@altshulerberzon.com

Michelle Banker (admitted *pro hac vice*)  
Alison Tanner (admitted *pro hac vice*)  
Noel León (admitted *pro hac vice*)  
Sudria Twyman (admitted *pro hac vice*)  
**NATIONAL WOMEN’S LAW CENTER**  
1350 I Street NW, Suite 700  
Washington, DC 20005  
Tel: 202.588.5180  
Email: mbanker@nwlc.org  
atanner@nwlc.org  
nleon@nwlc.org  
stwyman@nwlc.org

21 *Attorneys for Plaintiff and the Putative Class*

22 UNITED STATES DISTRICT COURT  
23 NORTHERN DISTRICT OF CALIFORNIA  
24 OAKLAND DIVISION

25 MARA BERTON, on behalf of herself and  
26 all others similarly situated,

27 Plaintiff,

28 v.

AETNA INC. and AETNA LIFE  
INSURANCE COMPANY,

Defendants.

CASE NO.: 4:23-cv-01849-HSG

**PLAINTIFF’S OPPOSITION TO  
DEFENDANTS’ MOTION TO DISMISS**

Date: October 12, 2023  
Time: 2:00 p.m.  
Dept.: Courtroom 2, 4th Floor  
Judge: Hon. Haywood S. Gilliam

**REDACTED VERSION FOR  
PUBLIC FILING**

**TABLE OF CONTENTS**

	<b>Page(s)</b>
TABLE OF AUTHORITIES .....	iv
INTRODUCTION .....	3
STATEMENT OF FACTS .....	3
A. Aetna Designs Markets, Sells, and Administers Health Plans Nationwide that Incorporate Aetna’s Own Clinical Policy Bulletin on Infertility.....	3
B. Aetna’s Infertility Policy Imposes More Burdensome and Costly Eligibility Requirements on LGBTQ Members in Same-Sex Relationships Than on Members in Heterosexual Relationships .....	3
C. Aetna Denied Plaintiff’s Benefits Claim Based on Its Own Infertility Policy .....	5
D. Plaintiff Filed This Action Alleging a Section 1557 Claim .....	5
LEGAL STANDARD.....	6
ARGUMENT .....	6
I. Plaintiff Properly Pleads a Section 1557 Claim for Intentional Discrimination.....	6
A. Aetna’s Infertility Policy Is Facially Discriminatory.....	9
B. Aetna’s Enforcement of Its Policy Intentionally Discriminates Against LGBTQ Members.....	13
II. Aetna’s Rule 12(b)(7) Motion Should be Denied Because Encore Is Not a Necessary Party, Let Alone an Indispensible One.....	15
A. Encore Is Not a Necessary Party Under Rule 19(a).....	15
1. Encore Is Not Necessary to Afford Plaintiff Complete Relief for Her Claims Against Aetna Under Section 1557 .....	15
2. Encore Has Not Claimed Any Interest in This Litigation, Nor Has Aetna Identified Any Legally Protected Interest Encore Could Claim .....	18
B. Even If Encore Were a Necessary Party, Dismissal Would Be Improper Because Encore Can Feasibly Be Joined .....	21
C. Even If Joinder of Encore Were Not Feasible, Equity and Good Conscience Preclude Dismissal Under Rule 19(b).....	22

1 III. ERISA Does Not Preempt Plaintiff’s Section 1557 Claim .....24  
2 IV. Defendants’ Attempt to Dismiss Aetna Inc. Under Rule 12(b)(6)  
3 Is Improper .....25  
4 CONCLUSION.....25  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**TABLE OF AUTHORITIES**

**Page(s)**

**Cases**

*Aetna Health Inc. v. Davila*,  
542 U.S. 200 (2004).....25

*Almont Ambulatory Surgery Ctr., LLC v. UnitedHealth Grp., Inc.*,  
99 F.Supp.3d 1110 (C.D. Cal. 2015) .....23

*Almont Ambulatory Surgery Ctr., LLC v. UnitedHealth Grp., Inc.*,  
No. CV 14-3053-MWF, 2018 WL 11241771 (C.D. Cal. Apr. 11, 2018).....19

*Alto v. Black*,  
738 F.3d 1111 (9th Cir. 2013) .....2, 15, 21

*Am. Greyhound Racing, Inc. v. Hull*,  
305 F.3d 1015 (9th Cir. 2002) .....23

*Ariz. Dream Act Coal. v. Brewer*,  
855 F.3d 957 (9th Cir. 2017) .....14

*Austin v. Univ. of Or.*,  
925 F.3d 1133 (9th Cir. 2019) .....13, 14

*Baird v. Blackrock Institutional Tr. Co., N.A.*,  
No. 17-CV-01892-HSG, 2020 WL 7389772 (N.D. Cal. Feb. 11, 2020).....23

*Bostock v. Clayton County*,  
140 S.Ct. 1731 (2020)..... *passim*

*Boyden v. Conlin*,  
341 F.Supp.3d 979 (W.D. Wisc. 2018).....7, 10

*Briscoe v. Health Care Serv. Corp.*,  
281 F.Supp.3d 725 (N.D. Ill. 2017) .....10

*C.P. by & through Pritchard v. Blue Cross Blue Shield of Ill.*,  
No. 3:20-CV-06145-RJB, 2022 WL 17788148 (W.D. Wash. Dec. 19, 2022).....7, 17, 24

*Cachil Dehe Band of Wintun Indians v. California*,  
547 F.3d 962 (9th Cir. 2008) .....15

*Carr v. United Healthcare Servs. Inc.*,  
No. C15-1105-MJP, 2016 WL 7716060 (W.D. Wash. May 31, 2016).....16, 18

*Christian Legal Soc. Chapter of the Univ. of Cal., Hastings v. Martinez*,  
561 U.S. 661 (2010).....11

1 *City of Royal Oak Retirement Sys. v. Juniper Networks, Inc.*,  
880 F.Supp.2d 1045 (N.D. Cal. 2012) .....25

2 *Columbus Bd. of Educ. v. Penick*,  
3 443 U.S. 449 (1979).....14

4 *Comm. Concerning Cmty. Improvement v. City of Modesto*,  
5 583 F.3d 690 (9th Cir. 2009) .....14

6 *Conner v. Burford*,  
848 F.2d 1441 (9th Cir. 1998) .....24

7 *Cuevas v. Joint Benefit Tr.*,  
8 No. 13-CV-00045-JST, 2013 WL 3578496 (N.D. Cal. July 12, 2013).....23

9 *Cummings v. Premier Rehab Keller, P.L.L.C.*,  
10 142 S.Ct. 1562 (2022).....16

11 *Davis v. Guam*,  
932 F.3d 822 (9th Cir. 2019) .....1, 10

12 *Disabled Rts. Action Cmty. v. Las Vegas Events, Inc.*,  
13 375 F.3d 861 (9th Cir. 2004) ..... *passim*

14 *Doe v. Snyder*,  
28 F.4th 103 (9th Cir. 2022) .....1, 7, 8

15 *Fain v. Crouch*,  
16 618 F.Supp.3d 313 (S.D.W. Va. 2022).....7, 11

17 *Fossen v. Blue Cross & Blue Shield of Mont., Inc.*,  
18 660 F.3d 1102 (9th Cir. 2011) .....25

19 *Frank v. United Airlines, Inc.*,  
20 216 F.3d 845 (9th Cir. 2000) .....8, 10

21 *Frappied v. Affinity Gaming Black Hawk, LLC*,  
966 F.3d 1038 (10th Cir. 2020) .....12

22 *Gerdorn v. Cont’l Airlines, Inc.*,  
23 692 F.2d 602 (9th Cir. 1982) (en banc) .....2, 8

24 *Hammons v. Univ. of Md. Med. Sys. Corp.*,  
-- F.Supp.3d --, 2023 WL 121741 (D. Md. Jan. 6, 2023).....7, 10

25 *Hammons v. Wells Fargo Bank, N.A.*,  
26 No. 15-CV-04897-RS, 2015 WL 9258092 (N.D. Cal. Dec. 18, 2015).....20

27 *Hecox v. Little*,  
28 No. 20-35813, -- F.4th --, 2023 WL 5283127 (9th Cir. Aug. 17, 2023).....1, 11

1 *Kermanshah v. Kermanshah*,  
 No. 08-CV-409, 2010 WL 1904135 (S.D.N.Y. May 11, 2010) .....23

2 *Kescoli v. Babbitt*,  
 3 101 F.3d 1304 (9th Cir. 1996) .....22, 23, 24

4 *Khoja v. Orexigen Therapeutics, Inc.*,  
 5 899 F.3d 988 (9th Cir. 2018) .....6, 25

6 *Koala v. Khosla*,  
 931 F.3d 887 (9th Cir. 2019) .....6

7 *Lawrence v. Texas*,  
 8 539 U.S. 558 (2003).....11

9 *Lea v. Republic Airlines, Inc.*,  
 10 903 F.2d 624 (9th Cir. 1990) .....25

11 *Lewis v. Clarke*,  
 581 U.S. 155 (2017).....16

12 *Lomayaktewa v. Hathaway*,  
 13 520 F.2d 1324 (9th Cir. 1975) .....23

14 *Los Angeles Dept. of Water & Power v. Manhart*,  
 435 U.S. 702 (1978).....13

15 *Loving v. Virginia*,  
 16 388 U.S. 1 (1967).....8

17 *In re Lowenschuss*,  
 18 171 F.3d 673 (9th Cir. 1999) .....23

19 *Makah Indian Tribe v. Verity*,  
 910 F.2d 555 (9th Cir. 1990) .....6, 19, 22, 23

20 *McGary v. City of Portland*,  
 21 386 F.3d 1259 (9th Cir. 2004) .....6

22 *McGinest v. GTE Serv. Corp.*,  
 23 360 F.3d 1103 (9th Cir. 2004) .....8

24 *Mewawalla v. Middleman*,  
 601 F.Supp.3d 574 (N.D. Cal. 2022) .....22

25 *U.S. ex rel. Morongo Band of Mission Indians v. Rose*,  
 26 34 F.3d 901 (9th Cir. 1994) .....19

27 *Northrop Corp. v. McDonnell Douglas Corp.*,  
 28 705 F.2d 1030 (9th Cir. 1983) .....19

1 *Pac. Shores Props., LLC v. City of Newport Beach*,  
 730 F.3d 1142 (9th Cir. 2013) .....11, 12, 13

2 *Paiute-Shoshone Indians of Bishop Cmty. v. City of Los Angeles*,  
 3 637 F.3d 993 (9th Cir. 2011) .....6, 16

4 *Parr v. Woodmen of the World Life Ins. Co.*,  
 5 791 F.2d 888 (11th Cir. 1986) .....8

6 *Phillips v. Martin Marietta Corp.*,  
 400 U.S. 542 (1971) (per curiam).....12

7 *Physics, Materials & Applied Mathematics Rsch. LLC v. Yeak*,  
 8 No. CV-20-00379-TUC-JCH, 2022 WL 3286585 (D. Ariz. Aug. 11, 2022).....18, 19

9 *Pilot Life Ins. Co. v. Dedeaux*,  
 481 U.S. 41 (1987).....25

10 *Polonczyk v. Anthem BlueCross & BlueShield*,  
 11 586 F.Supp.3d 648 (E.D. Ky. 2022) .....10

12 *Price Waterhouse v. Hopkins*,  
 13 490 U.S. 228 (1989).....8

14 *Rice v. Cayetano*,  
 528 U.S. 495 (2000).....12, 13

15 *Roberts v. City of Fairbanks*,  
 16 947 F.3d 1191 (9th Cir. 2020) .....19

17 *Salt River Project Agr. Imp. & Power Dist. v. Lee*,  
 18 672 F.3d 1176 (9th Cir. 2012) .....18

19 *Schwarzenegger v. Fred Martin Motor Co.*,  
 374 F.3d 797 (9th Cir. 2004) .....21

20 *Scott v. St. Louis Univ. Hosp.*,  
 21 600 F.Supp.3d 956 (E.D. Mo. 2022).....25

22 *Sher v. Johnson*,  
 23 911 F.2d 1357 (9th Cir. 1990) .....22

24 *Starr v. Baca*,  
 652 F.3d 1202 (9th Cir. 2011) .....6

25 *Sypher v. Aetna Ins. Co.*,  
 26 No. 13-10007, 2014 WL 1230028 (E.D. Mich. Mar. 25, 2014).....23

27 *Takeda v. Northwestern National Life Insurance Co.*,  
 28 765 F.2d 815 (9th Cir. 1985) .....21, 23

1 *Taylor v. Accredited Home Lenders, Inc.*,  
580 F.Supp.2d 1062 (S.D. Cal. 2008).....25

2 *Tovar v. Essentia Health*,

3 342 F.Supp.3d 947 (D. Minn. 2018).....8, 16, 17, 25

4 *Tovar v. Essentia Health*,

5 857 F.3d 771 (8th Cir. 2017) .....16, 17

6 *UAW v. Johnson Controls, Inc.*,

499 U.S. 187 (1991).....8, 12

7 *United States v. Bowen*,

8 172 F.3d 682 (9th Cir. 1999) .....2, 18

9 *Vill. of Arlington Heights v. Metro. Hous. Dev. Corp.*,

10 429 U.S. 252 (1977).....14

11 *Ward v. Apple Inc.*,

791 F.3d 1041 (9th Cir. 2015) .....2, 16, 19

12 *Weinreb v. Xerox Business Services*,

13 323 F.Supp.3d 501 (S.D.N.Y. 2018).....10

14 *Weiss v. Perez*,

15 602 F.Supp.3d 1279 (N.D. Cal. 2022) .....20

16 *Wilson v. Metals USA, Inc.*,

No. CIV S-12-0568 LKK, 2012 WL 5932990 (E.D. Cal. Nov. 27, 2012).....22

17 *Yick Wo v. Hopkins*,

18 118 U.S. 356 (1886).....14

19 *Zarda v. Altitude Express, Inc.*,

20 883 F.3d 100 (2d Cir. 2018) (en banc).....8

21 **Statutes**

22 20 U.S.C. §1681 .....7

23 28 U.S.C. §1391(b)(2) .....22

24 29 U.S.C. §1104(a)(1)(D) .....24

25 29 U.S.C. §1132(a)(1)(B) .....15, 24

26 29 U.S.C. §1132(a)(3).....16

27 29 U.S.C. §1144(d) .....24

28 42 U.S.C. §18116(a) .....1, 7



**Other Authorities**

1

2 Fed. R. Civ. P. 4(k)(1)(A).....21

3 Fed. R. Civ. P. 19..... *passim*

4 Fed. R. Civ. P. 56(d).....25

5 7 Charles Alan Wright & Arthur R. Miller, *Fed. Practice & Procedure* §1609 (3d

6 ed. 2015) .....6

7 Lisette Johnson, Ins. Circular Letter No. 3, *Health Insurance Coverage of*

8 *Infertility Treatments Regardless of Sexual Orientation or Gender Identity,*

9 *N.Y.*.....14

10 *Notice of Proposed Rulemaking, Nondiscrimination in Health Programs and*

11 *Activities*, 87 Fed. Reg. 47,824, 47,825 (Aug. 4, 2022).....24

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

## INTRODUCTION

1  
2 Plaintiff Mara Berton (“Plaintiff”) brings this lawsuit to hold Defendants Aetna Life  
3 Insurance Company and Aetna Inc. (together, “Aetna” or “Defendants”) accountable under  
4 Section 1557 of the Affordable Care Act, 42 U.S.C. §18116(a) (“Section 1557”) for designing,  
5 marketing, selling, and administering health benefit plans that facially discriminate on the basis  
6 of sexual orientation and/or gender identity in the provision of fertility benefits coverage. Aetna-  
7 designed and -administered health plans, like the one Plaintiff and her wife are members of,  
8 allow members who engage in “heterosexual sexual intercourse” to establish their “infertility”  
9 (as defined by Aetna) and access covered fertility benefits simply by representing that they have  
10 been unable to conceive after one year of frequent intercourse with their partner. But for Plaintiff  
11 and other LGBTQ members seeking fertility benefits who are unable to get pregnant through  
12 intercourse with their partner due to their sexual orientation and/or gender identity, Aetna  
13 imposes vastly more onerous and expensive eligibility criteria. Specifically, Aetna requires  
14 LGBTQ members to prove their “infertility” (as defined by Aetna) by paying for and undergoing  
15 12 cycles of artificial insemination treatments—a process that takes longer than 12 months, often  
16 costs members thousands of dollars out of pocket, and generally is more cycles than is medically  
17 advised. Aetna’s “Infertility Policy” thus on its face treats LGBTQ members like Plaintiff worse  
18 than similarly situated members in heterosexual relationships, in plain violation of Section 1557.  
19 *See Doe v. Snyder*, 28 F.4th 103, 113–14 (9th Cir. 2022).

20 Despite Plaintiff’s clear allegations of facial discrimination, Aetna moves to dismiss  
21 under Rule 12(b)(6). Aetna’s argument is based on a gross mischaracterization of Aetna’s  
22 Infertility Policy as “facially neutral” and a misstatement of the law as requiring proof of animus,  
23 which it does not. By imposing different burdens based on whether a member engages in  
24 “heterosexual sexual intercourse”—a “proxy” for sexual orientation—the Policy on its face treats  
25 Plaintiff worse than similarly situated members in heterosexual relationships, based on her  
26 sexual orientation. *See Hecox v. Little*, No. 20-35813, -- F.4th --, 2023 WL 5283127, at \*10 (9th  
27 Cir. Aug. 17, 2023); *Davis v. Guam*, 932 F.3d 822, 837 (9th Cir. 2019). Simply put, if Plaintiff’s  
28 partner were a man rather than a woman, she would have a cost-free path to access fertility

1 benefits, instead of having to pay thousands of dollars out of pocket and having to undergo  
2 medically unnecessary treatments that could harm her health. *See Bostock v. Clayton County*, 140  
3 S.Ct. 1731 (2020). Because the Policy discriminates on its face, no separate proof of animus is  
4 required. *See Gerdom v. Cont'l Airlines, Inc.*, 692 F.2d 602, 608 (9th Cir. 1982) (en banc).

5 In a further attempt to shield itself from having to face suit for its own conduct in  
6 designing, marketing, selling, and administering discriminatory health plans, Aetna also seeks  
7 dismissal pursuant to Rule 12(b)(7), arguing that Plaintiff's wife's employer Encore Group USA  
8 LLC ("Encore"), the plan sponsor to whom Aetna sold its discriminatory health plan design, is  
9 an "indispensable" party that cannot be joined. Aetna's misuse of Rule 19 fails at every turn.  
10 First, Encore is not a necessary party because Plaintiff can obtain complete relief from Aetna for  
11 her Section 1557 claim. *See Fed. R. Civ. P. 19(a)(1)(A)*. Aetna mischaracterizes Plaintiff's claim  
12 as an ERISA one, but Plaintiff does not contend that Aetna incorrectly administered the Plan;  
13 rather, she claims that Aetna's discriminatory Plan design denies her and class members equal  
14 access to Plan benefits. Plaintiff does not seek payment of benefits owed under the Plan or  
15 equitable relief pursuant to ERISA, but rather damages and an injunction against Aetna alone  
16 pursuant to Section 1557. Even if Encore may be separately liable under other legal theories, "it  
17 is not necessary for all joint tortfeasors to be named as defendants in a single lawsuit." *E.g.*,  
18 *Ward v. Apple Inc.*, 791 F.3d 1041, 1048 (9th Cir. 2015). Second, Encore has not claimed *any*  
19 interest in this action, let alone a "legally protected" one. *See United States v. Bowen*, 172 F.3d  
20 682, 689 (9th Cir. 1999); *Fed. R. Civ. P. 19(a)(1)(B)*. Aetna's motion therefore fails "at step one"  
21 of the Rule 19 analysis. *See Alto v. Black*, 738 F.3d 1111, 1126 (9th Cir. 2013); *Disabled Rts.*  
22 *Action Cmty. v. Las Vegas Events, Inc.*, 375 F.3d 861, 883 (9th Cir. 2004). Moreover, even if  
23 Encore were necessary, dismissal would be improper because Encore may feasibly be joined.  
24 Further, equity and good conscience and the public interest preclude dismissal.

25 Finally, ERISA does not preempt *federal* claims like Section 1557, and Aetna Inc.'s  
26 motion for dismissal improperly rests on extraneous materials not incorporated into the  
27 complaint. Aetna's motion should be denied in full.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

## STATEMENT OF FACTS

### A. Aetna Designs, Markets, Sells, and Administers Health Plans Nationwide that Incorporate Aetna’s Own Clinical Policy Bulletin on Infertility.

Aetna is a nationwide company that provides health coverage products, including fully-insured and self-funded health benefit plans. Compl. ¶¶14–15.<sup>1</sup> For self-funded plans, Aetna designs and markets plans that it offers for sale to employers and other plan sponsors, for which Aetna then acts as a third-party administrator (“TPA”). *Id.* ¶18. For all health plans that Aetna designs, markets, sells, supplies, issues, and administers, Aetna by default incorporates a series of “Clinical Policy Bulletins” (“CPBs”) it develops and publishes, and in general Aetna requires those buying its TPA services to agree to the terms set forth therein. *Id.* ¶¶22, 26. Aetna claims full responsibility for the content of these CPBs, which “express Aetna’s determination of whether certain services or supplies are medically necessary, experimental and investigational, or cosmetic,” and which Aetna applies when making coverage eligibility determinations. *Id.* ¶¶23–24; *see id.* ¶¶22, 26; Dkt. 40-2, Exh. B to the Decl. of Robert Goldbeck, Encore Group Policy Summary Plan Document (“SPD”) at 36; Dkt. 40-3, Exh. A to the Decl. of Donna Lynch. For Aetna-designed and -administered health plans that provide coverage for infertility treatments, Aetna by default incorporates into those plans Clinical Policy Bulletin No. 0327—Infertility (referred to herein as the “Infertility Policy” or “Policy”), which Aetna designed specifically to govern its determination of members’ eligibility for fertility benefits. Compl. ¶¶25–27.

### B. Aetna’s Infertility Policy Imposes More Burdensome and Costly Eligibility Requirements on LGBTQ Members in Same-Sex Relationships Than on Members in Heterosexual Relationships.

Prior to January 2023, Aetna’s Infertility Policy stated, in relevant part:

For purposes of this policy, a member is considered infertile if he or she is unable to conceive or produce conception after **1 year of frequent, unprotected heterosexual sexual intercourse**, or **6 months of frequent, unprotected heterosexual sexual intercourse** if the female partner is 35 years of age or older. **Alternately, a woman without a male partner** may be considered infertile if she is unable to conceive or produce conception after **at least 12 cycles of donor insemination** (6 cycles for women 35 years of age or older).

27  
28

---

<sup>1</sup> In a fully insured plan, the plan sponsor purchases insurance that is underwritten by an issuer like Aetna. In a self-funded plan, the claims are paid by the plan sponsor, but a self-funded plan will often contract with a third-party claims administrator like Aetna to administer the plan.

1 *Id.* ¶28; Mot. at 5–6. Under the express terms of this Policy, a member in a heterosexual  
 2 relationship could meet Aetna’s definition of infertility by engaging in *either* (1) “1 year of  
 3 frequent, unprotected heterosexual sexual intercourse” *or* (2) 12 cycles of “donor insemination”;<sup>2</sup>  
 4 but only the latter option was available to a member in a same-sex relationship.<sup>3</sup> Compl. ¶29.

5 In January 2023, Aetna altered the language but not the substance of its definition of  
 6 “infertile” in its Infertility Policy to state, in relevant part:

7 For purposes of this policy, a person is considered infertile if unable to conceive or  
 8 produce conception after **1 year of egg-sperm contact** when the female attempting  
 9 conception is under 35 years of age, **or after 6 months [of] egg-sperm contact**  
 10 when the female attempting conception is 35 years of age or older. **Egg-sperm**  
 11 **contact can be achieved by frequent sexual intercourse or through monthly**  
 12 **cycles of timed sperm insemination (intrauterine, intracervical, or**  
 13 **intravaginal).** This definition applies to all individuals regardless of sexual  
 14 orientation or the presence/availability of a reproductive partner.

15 *Id.* ¶30. Under both versions of the Infertility Policy, people in heterosexual relationships can  
 16 establish their eligibility for fertility benefits simply by representing that they have been unable  
 17 to conceive after one year of “frequent” sexual intercourse. Compl. ¶33. The Policy does not  
 18 define “frequent,” nor does it require documentation of the timing of intercourse. *Id.* ¶¶33–35.

19 By contrast, Aetna’s Policy requires members in non-heterosexual relationships to pay  
 20 thousands of dollars out of pocket for fertility treatments, because IUI—the most common  
 21 method of donor insemination—costs at least hundreds of dollars per cycle. *Id.* ¶41. Moreover,  
 22 Aetna’s Policy necessitates greater delays before access to covered treatment is granted for  
 23 LGBTQ couples because undergoing 12 cycles of donor insemination takes longer than 12  
 24 months. *Id.* ¶¶38–42. And Aetna’s Policy requires plan members in LGBTQ relationships to  
 25 undergo procedures that may be contrary to medical advice. *Id.* ¶¶43–44. For affected members  
 26 who do not have the funds to pay out of pocket for fertility treatment before qualifying for  
 27 coverage, Aetna’s requirement blocks access to needed benefits entirely. *Id.* ¶¶47–48.

28 <sup>2</sup> For members over 35, these requirements are reduced to six months of frequent, unprotected  
 heterosexual sexual intercourse or six cycles of donor insemination. Compl. ¶29.

<sup>3</sup> As the Policy uses the term “woman,” Plaintiff at times refers to members who wish to get  
 pregnant as “women” and to the relationships of those whose partners are considered female  
 under the Policy as “same-sex relationships,” but Plaintiff recognizes that putative class  
 members and their partners hold a range of gender identities and may not be of the same sex.

1 **C. Aetna Denied Plaintiff’s Benefits Claim Based on Its Own Infertility Policy.**

2 Plaintiff is a 32-year-old woman married to a woman. Compl. ¶¶13, 52. Since September  
3 10, 2021, Plaintiff has been enrolled in a health plan sponsored by her wife’s employer, Encore  
4 (“Plan”)—a plan that Aetna designed, marketed, and sold to Encore, and that Aetna administers.  
5 *Id.* ¶¶52, 55. The Plan generally provides coverage for the diagnosis and treatment of infertility  
6 as well as “[c]omprehensive infertility services,” including “artificial insemination, which  
7 includes intrauterine (IUI)/intracervical (ICI) insemination.” *Id.* ¶¶54–55; SPD at 10–11. The  
8 Plan provides that members are eligible for covered infertility treatments if they “have met the  
9 requirement for the number of months trying to conceive through egg and sperm contact” or  
10 meet the Plan’s definition of “infertility”—which precisely tracks the definition of “infertility” in  
11 Aetna’s Infertility Policy. SPD at 11, 57–58.

12 Plaintiff and her wife want a family with at least two children. *Id.* ¶56. In January 2022,  
13 they decided to start pursuing fertility treatments for Plaintiff, because they cannot become  
14 pregnant through sexual intercourse. *Id.* ¶57. Plaintiff’s physician advised IUI, and her clinic  
15 submitted a claim to Aetna for preauthorization of that treatment. *Id.* ¶¶57–58. Aetna denied  
16 coverage. *Id.* ¶59. Plaintiff appealed that denial, explaining, “I am unable to engage in ‘frequent,  
17 unprotected heterosexual sexual intercourse’ because I am a woman married to a woman.” *Id.*  
18 ¶61. Aetna denied Plaintiff’s appeal, explaining that Aetna did not consider her “infertile,” using  
19 language from Aetna’s Infertility Policy:

20 *We consider an individual infertile if the individual is unable to conceive or produce*  
21 *conception after one (1) year of frequent, unprotected heterosexual sexual*  
22 *intercourse, or six (6) months of frequent, unprotected heterosexual sexual*  
23 *intercourse if the female partner is 35 years of age or older. Alternately, a woman*  
24 *without a male partner may be considered infertile if she is unable to conceive or*  
*produce conception after at least twelve (12) cycles of donor insemination (six (6)*  
*cycles for women 35 years of age or older). Meeting the definition of infertility is*  
*a requirement of the member’s insurance plan. Our records don’t show the member*  
*meet [sic] these criteria.*

25 Compl. ¶62 (emphasis added); Lynch Decl., Exh. C. Plaintiff filed a second appeal of this  
26 determination, which Aetna also denied on the same basis. Compl. ¶63.

27 **D. Plaintiff Filed This Action Alleging a Section 1557 Claim.**

28 Plaintiff filed this action on April 17, 2023, alleging Aetna’s facially discriminatory

1 Policy violates Section 1557 of the ACA. Compl. ¶¶66–69, 95–102. Plaintiff seeks relief on  
 2 behalf of a National Injunctive Relief Class and a California Damages Class. *Id.* ¶¶76–78.

### 3 LEGAL STANDARD

4 In adjudicating a motion to dismiss under Rule 12(b)(6), the court “accept[s] the  
 5 complaint’s well-pleaded factual allegations as true, and construe[s] all inferences in the  
 6 plaintiff’s favor.” *Koala v. Khosla*, 931 F.3d 887, 894 (9th Cir. 2019) (citation omitted). No  
 7 materials may be considered other than the factual allegations in the complaint and documents  
 8 incorporated therein by reference. *Khoja v. Orexigen Therapeutics, Inc.*, 899 F.3d 988, 998 (9th  
 9 Cir. 2018).<sup>4</sup> If the complaint states a plausible case, it “survives a motion to dismiss” even if  
 10 defendant asserts alternative explanations that are also “plausible.” *Starr v. Baca*, 652 F.3d 1202,  
 11 1216 (9th Cir. 2011). Rule 12(b)(6) motions are generally disfavored and are “especially  
 12 disfavored” when a complaint alleges a legal theory “that can best be assessed after factual  
 13 development.” *McGary v. City of Portland*, 386 F.3d 1259, 1270 (9th Cir. 2004).

14 In ruling on a Rule 12(b)(7) motion, the Court likewise must “accept as true the  
 15 allegations in Plaintiff’s complaint and draw all reasonable inferences in Plaintiff’s favor.”  
 16 *Paiute-Shoshone Indians of Bishop Cmty. v. City of Los Angeles*, 637 F.3d 993, 996 n.1 (9th Cir.  
 17 2011). “The moving party has the burden of persuasion in arguing for dismissal.” *Makah Indian*  
 18 *Tribe v. Verity*, 910 F.2d 555, 558 (9th Cir. 1990). Courts are “extremely reluctant to grant  
 19 motions to dismiss based on nonjoinder and, in general, dismissal will be ordered only when the  
 20 defect cannot be cured and serious prejudice or inefficiency will result.” 7 Charles Alan Wright  
 21 & Arthur R. Miller, *Fed. Practice & Procedure* §1609 (3d ed. 2015).

### 22 ARGUMENT

#### 23 I. Plaintiff Properly Pleads a Section 1557 Claim for Intentional Discrimination.

24 Section 1557 of the ACA provides that “an individual shall not, on the ground prohibited

25 \_\_\_\_\_  
 26 <sup>4</sup> Documents are incorporated only “if the plaintiff refers extensively to the document or the  
 27 document forms the basis of the plaintiff’s claim.” *Khoja*, 899 F.3d at 1002 (citation omitted).  
 28 Aetna asserts without citation that its Master Services Agreement with Encore (“MSA”) is  
 incorporated into the Complaint. Mot. at 3, n.2. In reality, the Complaint does not refer to the  
 MSA at all, let alone extensively, nor does the MSA form the basis of Plaintiff’s claim. The  
 MSA and related declarations thus can be considered only for Rule 12(b)(7), not Rule 12(b)(6).

1 under ... title IX of the Education Amendments of 1972 ... be excluded from participation in, be  
 2 denied the benefits of, or be subjected to discrimination under, any health program or activity,  
 3 any part of which is receiving Federal financial assistance.” 42 U.S.C. §18116(a).<sup>5</sup> Title IX  
 4 prohibits discrimination “on the basis of sex,” 20 U.S.C. §1681, and courts “construe Title IX’s  
 5 protections consistently with those of Title VII,” including in Section 1557 claims. *Snyder*, 28  
 6 F.4th at 114. Accordingly, just as discrimination based on sexual orientation or gender identity is  
 7 unlawful under Title VII, *see Bostock*, 140 S.Ct. 1731,<sup>6</sup> so too is it unlawful under Title IX and  
 8 Section 1557, which Aetna does not dispute. *Snyder*, 28 F.4th at 114 (*Bostock* analysis applies to  
 9 sex discrimination claims under Title IX and Section 1557); *see also Hammons v. Univ. of Md.*  
 10 *Med. Sys. Corp.*, -- F.Supp.3d --, 2023 WL 121741, at \*7–10 (D. Md. Jan. 6, 2023); *Pritchard*,  
 11 2022 WL 17788148, at \*6; *Fain v. Crouch*, 618 F.Supp.3d 313, 335 (S.D.W. Va. 2022); *Boyden v.*  
 12 *Conlin*, 341 F.Supp.3d 979, 995–97 (W.D. Wisc. 2018).

13 Plaintiff plausibly alleges that Aetna discriminated and continues to discriminate against  
 14 her and putative class members on the basis of sexual orientation and gender identity by  
 15 designing, marketing, selling, and/or administering health plans that incorporate Aetna’s  
 16 Infertility Policy, which imposes significantly more burdensome requirements on LGBTQ  
 17 members in same-sex partnerships seeking fertility benefits than it does on cisgender members in  
 18 opposite-sex relationships. Compl. ¶¶1–7, 21–46, 52–65, 98. If Plaintiff were heterosexual and  
 19 married to a man instead of a woman, Aetna’s Policy would afford her a cost-free avenue to  
 20 coverage for fertility treatment—namely, representing that she was unable to conceive after one  
 21 year of frequent heterosexual intercourse. *Id.* Instead, because Plaintiff is married to a woman,  
 22 Aetna’s Policy requires her to spend thousands of dollars out of pocket to undergo 12 cycles of  
 23 artificial insemination (against medical advice) simply to establish eligibility for IUI coverage.  
 24 *Id.* ¶¶58–63. Aetna’s Policy thus treats Plaintiff “worse than others who are similarly situated,”

25 \_\_\_\_\_  
 26 <sup>5</sup> Aetna does not dispute that it is a covered entity under Section 1557, including with respect to  
 27 its TPA services. *See* Compl. ¶¶16, 69, 97; *C.P. by & through Pritchard v. Blue Cross Blue*  
*Shield of Ill.*, No. 3:20-CV-06145-RJB, 2022 WL 17788148, at \*8 (W.D. Wash. Dec. 19, 2022).

28 <sup>6</sup> *Bostock* recognized that “it is impossible to discriminate against a person for being homosexual  
 or transgender without discriminating against that individual based on sex.” 140 S.Ct. at 1741.



1 *Bostock*, 140 S.Ct. at 1740, meeting the straightforward definition of discrimination under Title  
 2 VII and, in turn, Title IX and Section 1557. *See Snyder*, 28 F.4th at 114.<sup>7</sup>

3 Aetna’s Rule 12(b)(6) motion to dismiss Plaintiff’s Section 1557 claim simply ignores  
 4 Plaintiff’s allegations and the applicable law. Instead, Aetna pretends that a plaintiff cannot state  
 5 a claim for sex discrimination under Section 1557 unless she alleges either “differential  
 6 treatment [that] is motivated by discriminatory animus toward the protected group” or deliberate  
 7 indifference “to a third-party’s discriminatory conduct.” Mot. at 9. But Aetna erroneously  
 8 conflates intentional discrimination and animus.<sup>8</sup> “Where a claim of discriminatory treatment is  
 9 based upon a policy which on its face applies less favorably to one gender,” the law is clear that  
 10 “the plaintiff need not otherwise establish the presence of discriminatory intent,” because the  
 11 policy itself provides sufficient evidence of intent. *Gerdom*, 692 F.2d at 608; *see UAW v.*  
 12 *Johnson Controls, Inc.*, 499 U.S. 187, 199 (1991) (“[T]he absence of a malevolent motive does  
 13 not convert a facially discriminatory policy into a neutral policy with a discriminatory effect.”).  
 14 Here, because Aetna’s Infertility Policy on its face imposes greater burdens on LGBTQ members  
 15 seeking to get pregnant with their same-sex partner than it does on similarly situated cisgender  
 16 members in opposite-sex relationships, Plaintiff need not separately allege that Aetna acted “out  
 17 of animus to women in same-sex relationships,” Mot. at 11. *See Frank v. United Airlines, Inc.*,  
 18 216 F.3d 845, 854 (9th Cir. 2000). Even if Aetna’s Infertility Policy could somehow be

19 \_\_\_\_\_  
 20 <sup>7</sup> Even if one were to characterize the discrimination here as based on the sex of Plaintiff’s  
 21 spouse, Aetna’s Infertility Policy would still violate Section 1557. *See Zarda v. Altitude Express,*  
 22 *Inc.*, 883 F.3d 100, 124–25 (2d Cir. 2018) (en banc) (Title VII prohibits “associational  
 23 discrimination,” including on the basis of sex), *aff’d sub nom. Bostock*, 140 S.Ct. 1731. Title  
 24 VII’s prohibition of associational discrimination based on race has long been established. *See,*  
 25 *e.g., McGinest v. GTE Serv. Corp.*, 360 F.3d 1103, 1118 (9th Cir. 2004) (Title VII “protect[s]  
 26 against adverse employment actions taken because of the employee’s close association with  
 27 black friends or coworkers”) (citations omitted); *Parr v. Woodmen of the World Life Ins. Co.*,  
 28 791 F.2d 888, 892 (11th Cir. 1986) (“Where a plaintiff claims discrimination based upon an  
 interracial marriage or association, he alleges, by definition, that he has been discriminated  
 against because of *his* race.”); *Zarda*, 883 F.3d at 124–25 (collecting cases); *cf. Loving v.*  
*Virginia*, 388 U.S. 1 (1967). Title VII “on its face treats each of the enumerated categories  
 exactly the same,” so principles applying to race discrimination apply with equal force to sex  
 discrimination. *Price Waterhouse v. Hopkins*, 490 U.S. 228, 243 n.9 (1989) (plurality opinion);  
*see Zarda*, 883 F.3d at 125.

<sup>8</sup> Where, as here, a Section 1557 plaintiff alleges that a plan is facially discriminatory, the  
 defendant already has actual notice, and a plaintiff need not allege facts showing deliberate  
 indifference. *See Tovar v. Essentia Health*, 342 F.Supp.3d 947, 953–54 (D. Minn. 2018).

1 construed as facially neutral (it cannot), Plaintiff adequately alleges that Aetna’s enforcement of  
2 the Policy intentionally discriminates against LGBTQ members seeking to get pregnant,  
3 supporting an inference of animus. *See infra* at 13. Aetna’s 12(b)(6) motion should be denied.

4 **A. Aetna’s Infertility Policy Is Facially Discriminatory.**

5 Aetna’s contention that its Infertility Policy “treats all persons seeking infertility  
6 treatments the same” because “they all must satisfy the definition of medical infertility,” Mot. at  
7 10, completely misses the mark. Because the Infertility Policy’s very “definition of medical  
8 infertility” imposes different standards and more onerous burdens for LGBTQ members in same-  
9 sex relationships than on members in heterosexual ones, the Policy is facially discriminatory.

10 On its face, Aetna’s Infertility Policy differentiates between members who engage in  
11 “heterosexual sexual intercourse” with a partner and those who do not. Compl. ¶¶28–31. Under  
12 the Policy, a cisgender member in a heterosexual relationship is deemed “infertile,” and thus  
13 eligible for covered fertility benefits, simply upon representing that the member has been unable  
14 to conceive after one year (or six months, depending on age) of “frequent [] heterosexual sexual  
15 intercourse” (pre-January 2023) or “frequent sexual intercourse” involving “egg-sperm contact”  
16 (post-January 2023), i.e., heterosexual sexual intercourse. *Id.* Such members are not required to  
17 provide any form of documentation of the sexual intercourse that satisfies this policy, nor must  
18 they incur *any* out-of-pocket costs, time their sexual intercourse with ovulation, meet any  
19 specific definition of “frequent,” or otherwise ensure they engage in sexual intercourse under  
20 conditions that could result in pregnancy. *Id.* ¶¶33–35. By contrast, an LGBTQ member in a  
21 same-sex relationship cannot access fertility benefits unless they first pay out of pocket for and  
22 undergo 12 (or six, depending on age) cycles of arduous artificial insemination treatments—a  
23 number of cycles that is often contrary to medical advice, and a process that takes longer than 12  
24 months and can be extremely expensive. *Id.* ¶¶4, 7, 28–31, 38–43, 50. Stated plainly, cisgender  
25 members in a heterosexual relationship are “taken at their word” that they are “infertile,” while  
26 LGBTQ members in a same-sex relationship are automatically deemed *ineligible* for otherwise-  
27 covered fertility benefits upon identifying their sexual orientation status unless they first spend  
28 “additional time and thousands of dollars” *proving* their infertility to Aetna. *Id.* ¶4.

1 Although Aetna tries to argue this is “at best a disparate impact theory of  
2 discrimination,”<sup>9</sup> Mot. at 11 (emphasis omitted), a “sex-differentiated ... standard that imposes  
3 unequal burdens” on different groups “is disparate treatment,” not simply disparate impact.  
4 *Frank*, 216 F.3d at 854–55 (holding that imposing “different *and more burdensome* weight  
5 standards” for women to meet compared to men constitutes disparate treatment). Because the  
6 express terms of Aetna’s Infertility Policy impose different and more burdensome standards for  
7 access to fertility treatment for people in LGBTQ relationships as compared to those who can  
8 have frequent “heterosexual sexual intercourse” with their partners, it discriminates on its face.<sup>10</sup>

9 Aetna’s contention that its Policy is facially neutral because it allows all members,  
10 regardless of sexual orientation, to meet its definition of infertility through either heterosexual  
11 sexual intercourse or artificial insemination is specious. “Proxy discrimination,” or  
12 discrimination based on superficially neutral categories fundamentally tied to protected  
13 characteristics, “is a form of facial discrimination.” *Davis*, 932 F.3d at 837 (quoting *McWright v.*  
14 *Alexander*, 982 F.2d 222, 228 (7th Cir. 1992)). Engaging in heterosexual sexual intercourse with

---

15  
16 <sup>9</sup> The Court should decline Aetna’s invitation to opine on whether a disparate impact theory of  
17 sex discrimination is cognizable under Section 1557, a question which has not been decided by  
18 either the Ninth Circuit or the U.S. Supreme Court. Plaintiff did not plead a disparate impact  
19 claim and had no need to do so because the policy she challenges is facially discriminatory.

20 <sup>10</sup> In its attempt to reframe Plaintiff’s theory of discrimination, Aetna relies on out-of-circuit  
21 district court decisions that do not bind this Court, and which are readily distinguishable. First,  
22 Aetna points to *Polonczyk v. Anthem BlueCross & BlueShield*, 586 F.Supp.3d 648, 656 (E.D. Ky.  
23 2022), in which a district court construed a plan’s denial of coverage for certain facial surgeries  
24 as applying to all individuals and facially neutral, and thus held that the plaintiff needed  
25 additional evidence of intent or deliberate indifference to challenge the “discriminatory  
26 consequences” for transgender individuals. *But see Boyden*, 341 F.Supp.3d at 995 (rejecting  
27 assumption that cosmetic surgeries for cisgender patients are comparable to gender-affirming  
28 surgeries for transgender patients). Here, there is no way to construe the Infertility Policy as  
doing anything other than applying two different standards that treat plan members differently  
based on sexual orientation and gender identity. *Cf. Hammons*, 2023 WL 121741, at \*9  
(distinguishing *Polonczyk*’s exclusion from a policy prohibiting hysterectomies only when  
performed for the purposes of gender-affirming care). Defendants’ reliance on *Weinreb v. Xerox*  
*Business Services*, 323 F. Supp. 3d 501 (S.D.N.Y. 2018), is similarly misplaced. The plan at  
issue in that case covered the use of fentanyl products only for breakthrough cancer pain, a  
policy that made no reference to or express distinction based on sex. *Id.* at 516. The court thus  
held that a plaintiff, who had a sex-specific disease other than cancer and was denied fentanyl  
under this facially neutral policy, needed to plausibly allege that the insurer intended “to interpret  
and apply the guidelines in a discriminatory way.” *Id.* at 521; *see also Briscoe v. Health Care*  
*Serv. Corp.*, 281 F.Supp.3d 725 (N.D. Ill. 2017) (granting motion to dismiss disparate impact  
claim). By contrast, Aetna’s intent here is clear from the terms of the Infertility Policy itself.

1 a partner is “so closely associated” with sexual orientation “that discrimination on the basis of  
2 such criteria is, constructively, facial discrimination against the disfavored group.” *See Pac.*  
3 *Shores Props., LLC v. City of Newport Beach*, 730 F.3d 1142, 1160 n.23 (9th Cir. 2013). Indeed,  
4 the Ninth Circuit recently reiterated that “classifying couples based on ‘procreative capacity’  
5 instead of sexual orientation” is an unlawful proxy for discrimination on the basis of sexual  
6 orientation. *Hecox*, 2023 WL 5283127, at \*10 (quoting *Latta v. Otter*, 771 F.3d 456, 467 (9th  
7 Cir. 2014)). The Supreme Court, too, has repeatedly recognized that discrimination against  
8 people based on the type of sexual intercourse they engage in is sexual orientation  
9 discrimination. *Christian Legal Soc. Chapter of the Univ. of Cal., Hastings v. Martinez*, 561 U.S.  
10 661, 689 (2010) (“Our decisions have declined to distinguish between status and conduct in this  
11 context.”); *Lawrence v. Texas*, 539 U.S. 558, 575 (2003) (“When homosexual *conduct* is made  
12 criminal by the law of the State, that declaration in and of itself is an invitation to subject  
13 homosexual *persons* to discrimination.” (emphasis added)). Aetna’s discrimination between  
14 members who engage in heterosexual intercourse and those who cannot because of their sexual  
15 orientation or gender identity is a proxy for sexual orientation discrimination.

16 Nor can Aetna defend its Policy on the ground that it may also impose burdens on some  
17 heterosexual women. *See Mot.* at 10. “Discriminatory laws, policies, or actions will often have  
18 negative effects...on individuals who do not belong to the disfavored group,” but that alone does  
19 not negate the fact that they are discriminatory. *Pac. Shores*, 730 F.3d 1142, 1160 (“The  
20 principle that overdiscrimination is prohibited undergirds all of constitutional and statutory anti-  
21 discrimination law....”). Here, that Aetna identifies other burdened groups or individuals does  
22 not change the fact that the Infertility Policy relies on a distinction between members who have  
23 “heterosexual sexual intercourse” with their partners and those who do not.

24 First, Aetna’s reference to “[s]ingle heterosexual women who wish to become parents on  
25 their own” is entirely irrelevant to the discrimination analysis here. The relevant inquiry is  
26 whether the plaintiff is treated differently than *similarly situated* individuals. *See Bostock*, 140  
27 S.Ct. at 1745; *Fain*, 618 F.Supp.3d at 325–26. For Plaintiff, a cisgender woman who is suffering  
28 discrimination based on her sexual orientation and the sex of her partner, the similarly situated

1 comparator is a woman whose partner is a man, not a woman without a partner at all. *Cf.*  
2 *Frappied v. Affinity Gaming Black Hawk, LLC*, 966 F.3d 1038, 1048 (10th Cir. 2020) (“Like any  
3 other sex-plus plaintiff, a sex-plus-age plaintiff must show unfavorable treatment relative to an  
4 employee of the opposite sex who also shares the ‘plus-’ characteristic.”). *Phillips v. Martin*  
5 *Marietta Corp.*, 400 U.S. 542 (1971) (per curiam) is instructive. In that case, a company policy  
6 that excluded women with young children but not men with young children from certain  
7 positions was facially discriminatory, notwithstanding that the policy did not exclude women  
8 *without* young children (thus treating women without young children and men without young  
9 children the same). *Id.* at 544; *see also Johnson Controls, Inc.*, 499 U.S. at 199 (policy barring  
10 only fertile women, but not fertile men or infertile women, from jobs entailing high levels of lead  
11 exposure was facially discriminatory). Likewise, that Aetna may treat single women of varying  
12 sexual orientations equally poorly does not cure its discriminatory treatment of members with  
13 partners on the basis of their sexual orientation or gender identity.

14 Aetna’s other examples of heterosexual women who may not be able to establish  
15 eligibility for fertility benefits through heterosexual intercourse are equally inapposite. *See Mot.*  
16 *at 10.* First, for couples who cannot engage in intercourse for certain medical reasons, Aetna’s  
17 policy *does* deem IUI to be necessary medical care for them without first requiring that they go  
18 through 12 or six cycles of artificial insemination. *See Decl. of Connie K. Chan iso Pl.’s Opp’n*  
19 *(“Chan Decl.”)* (CPB Section D(1)(d): “Aetna considers artificial insemination ... to be  
20 medically necessary for treatment of ... medically refractory erectile dysfunction or vaginismus  
21 preventing intercourse....”). Second, deployed military personnel and people in platonic  
22 relationships are neither similarly situated to Plaintiff nor protected classes under Section 1557.  
23 Moreover, Aetna offers no basis to conclude that it has any members in these groups seeking  
24 coverage for fertility benefits, nor can this be inferred from anything Plaintiff has alleged.  
25 Regardless, that Aetna contends it subjects some unspecified number of heterosexual women to  
26 disfavored treatment does not make its Infertility Policy facially neutral, where the Policy  
27 exclusively reserves the ability to obtain fertility treatment without out-of-pocket cost to people  
28 who engage in “heterosexual sexual intercourse.” *Cf. Pac. Shores*, 730 F.3d at 1160. In *Rice v.*

1 *Cayetano*, 528 U.S. 495 (2000), the Supreme Court rejected an argument analogous to Aetna’s.  
2 Hawaii argued that a statute favoring descendants of inhabitants of the islands in 1778, who were  
3 Polynesian, was not a proxy for race, as it excluded Polynesian people descended from later  
4 arrivals along with other races. *Id.* at 514. The Court held that “simply because a class defined by  
5 ancestry does not include all members of the race does not suffice to make the classification race  
6 neutral.” *Id.* at 516–17. Likewise, that Aetna’s favored classification does not include all  
7 heterosexuals does not make it facially neutral.

8 Finally, Aetna’s argument that its Infertility Policy neutrally applies “conventional  
9 medical criteria,” Mot. at 11, does not change this analysis. It is irrelevant what Aetna “might  
10 call its discriminatory practice, how others might label it, or what else might motivate it” because  
11 it treated Plaintiff less favorably because of her sex. *Bostock*, 140 S.Ct. at 1744. *Los Angeles*  
12 *Dept. of Water & Power v. Manhart*, 435 U.S. 702, 707–08 (1978), made clear that a policy  
13 informed by medical data that nevertheless treats women less favorably—there, a requirement  
14 that women contribute more to pension funds because of their longer average life expectancy—  
15 still discriminates because of sex. In any event, even if Aetna’s assertion that its Infertility Policy  
16 was justified by medical standards were legally relevant to whether the Policy is facially  
17 discriminatory (it is not), that assertion should nonetheless be disregarded entirely because it  
18 relies on factual assertions regarding “conventional medical criteria” and Aetna’s motivations  
19 which Plaintiff disputes, which are not found in the Complaint, and which are inappropriate for  
20 consideration on a motion to dismiss. Mot. at 5, n.5, 11-12. *See Austin v. Univ. of Or.*, 925 F.3d  
21 1133, 1136 (9th Cir. 2019).

22 **B. Aetna’s Enforcement of Its Policy Intentionally Discriminates Against LGBTQ**  
23 **Members.**

24 Because Aetna’s Infertility Policy is facially discriminatory, Plaintiff need not separately  
25 allege other facts showing that Aetna acted with invidious intent in order to establish a Section  
26 1557 violation. *See supra* at 8–9. But even if one were to pretend, as Aetna does, that the  
27 Infertility Policy is facially neutral, Plaintiff has still pled a plausible case of intentional  
28 discrimination. *See Pac. Shores*, 730 F.3d at 1158–59 (explaining courts must engage in

1 “‘sensitive’ multi-factor inquiry” into circumstantial and direct evidence to determine whether an  
 2 action was motivated by discriminatory intent) (citing *Vill. of Arlington Heights v. Metro. Hous.*  
 3 *Dev. Corp.*, 429 U.S. 252, 266–68 (1977)); *cf. Austin*, 925 F.3d at 1136 (Title IX plaintiff need  
 4 only satisfy Rule 8(a)’s liberal pleading standard).

5 Plaintiff alleges that cisgender members in a heterosexual relationship are “taken at their  
 6 word” that they are “infertile,” while LGBTQ members in a same-sex relationships must submit  
 7 documentation proving that they meet Aetna’s definition of infertility. Compl. ¶4; *see Yick Wo v.*  
 8 *Hopkins*, 118 U.S. 356, 373–74 (1886) (unequal application of neutral policy is evidence of  
 9 invidious intent); *Ariz. Dream Act Coal. v. Brewer*, 855 F.3d 957, 970 (9th Cir. 2017) (Mem.)  
 10 (same). Plaintiff also alleges Aetna is aware its discriminatory Policy effectively excludes most  
 11 LGBTQ members from accessing fertility benefits and causes LGBTQ members profound and  
 12 disproportionate harm. Compl. ¶¶6, 8; *see Columbus Bd. of Educ. v. Penick*, 443 U.S. 449, 464–  
 13 65 (1979) (foreseeable disproportionate consequences relevant evidence of purposeful  
 14 discrimination); *Comm. Concerning Cmty. Improvement v. City of Modesto*, 583 F.3d 690, 703  
 15 (9th Cir. 2009) (evidence of impact sufficient to create discriminatory inference of intent).  
 16 Indeed, in February 2021, the New York Department of Financial Services, the state agency that  
 17 regulates Aetna in New York, issued a bulletin stating explicitly that an insurance policy  
 18 requiring LGBTQ individuals to “incur costs ... that heterosexual individuals do not incur” as a  
 19 precondition for fertility treatments constitutes “discrimination due to their sexual orientation or  
 20 gender entity,” in violation of state law.<sup>11</sup> Yet rather than revise its Policy, Aetna simply  
 21 reworded the Policy in an attempt to better insulate itself from discrimination claims. *See* Compl.  
 22 ¶¶8, 31–32, 42–50, 70–75, 101; *see also Arlington Heights*, 429 U.S. at 267 (history of express  
 23 discrimination is relevant evidence of invidious purpose). Plaintiff has adequately pled animus,  
 24

25 <sup>11</sup> *See* Lisette Johnson, Ins. Circular Letter No. 3, *Health Insurance Coverage of Infertility*  
 26 *Treatments Regardless of Sexual Orientation or Gender Identity*, N.Y. Dep’t of Fin. Servs. (Feb.  
 27 23, 2021), <[https://www.dfs.ny.gov/industry\\_guidance/circular\\_letters/cl2021\\_03](https://www.dfs.ny.gov/industry_guidance/circular_letters/cl2021_03)>. Aetna’s  
 28 accusations of “bootstrapping” are thus wholly unfounded. Mot. at 12. Aetna was not merely  
 “accused of discrimination” by Plaintiff and others, *id.*; rather, a regulatory authority had  
 determined its Infertility Policy was discriminatory long before Plaintiff ever submitted her  
 appeals or any legal challenges to the Policy had been filed.

1 even though it is not necessary to succeed on her claim.

2 **II. Aetna’s Rule 12(b)(7) Motion Should Be Denied Because Encore Is Not a Necessary**  
3 **Party, Let Alone an Indispensable One.**

4 To meet its burden under Rule 12(b)(7), Aetna must first establish that Encore is a  
5 necessary party under Rule 19(a), either because (1) “the court cannot accord complete relief  
6 among existing parties” in its absence, Fed. R. Civ. P. 19(a)(1)(A), or (2) Encore has claimed a  
7 legally protected interest relating to the subject of the action, and proceeding with the suit in  
8 Encore’s absence will (a) “impair or impede [Encore’s] ability to protect” that claimed interest,  
9 or (b) “leave an existing party subject to a substantial risk of incurring double, multiple, or  
10 otherwise inconsistent obligations because of the interest,” Fed. R. Civ. P. 19(a)(1)(B). Only if  
11 Encore is necessary should the Court then consider whether it is feasible to join Encore. *See Alto*,  
12 738 F.3d at 1126. Finally, only if Encore is both necessary and joinder is infeasible must the  
13 Court then “determine whether, in equity and good conscience, the action should proceed among  
14 the existing parties or should be dismissed.” Fed. R. Civ. P. 19(b); *see Alto*, 738 F.3d at 1126.

15 Aetna’s motion fails at step one. Encore is not necessary to afford Plaintiff the relief she  
16 seeks against Aetna, and Encore has not claimed any interest in this litigation, let alone a legally  
17 protected one. Because Encore is not a necessary party under either subpart of Rule 19(a)(1),  
18 Aetna’s Rule 12(b)(7) motion must be denied, and the Court need not reach the considerations  
19 under Rule 19(b). *See Alto*, 738 F.3d at 1126; *Cachil Dehe Band of Wintun Indians v. California*,  
20 547 F.3d 962, 970 (9th Cir. 2008). Even if Encore were a necessary party, dismissal would still  
21 be improper because Encore may feasibly be joined and the balance of equities and the public  
22 interest favor allowing Plaintiff’s claims to proceed.

23 **A. Encore Is Not a Necessary Party Under Rule 19(a).**

24 **1. Encore Is Not Necessary to Afford Plaintiff Complete Relief for Her**  
25 **Claims Against Aetna Under Section 1557.**

26 Aetna mischaracterizes Plaintiff’s claim as an ERISA one seeking “payment of specific  
27 benefits under the Plan” and to “rewrite the terms of the Encore Plan,” and argues that Encore is  
28 a necessary party because it is the ERISA plan sponsor. Mot. at 15. But Plaintiff does not assert  
an ERISA claim for benefits pursuant to 29 U.S.C. §1132(a)(1)(B), nor does she seek equitable



1 relief under ERISA pursuant to 29 U.S.C. §1132(a)(3). Rather, Plaintiff asserts a single claim  
 2 against Aetna under Section 1557. Plaintiff seeks to recover from *Aetna*—not from the plan  
 3 sponsor—the damages she incurred as a result of *Aetna*’s enforcement of its discriminatory  
 4 Infertility Policy, as well as an injunction enjoining *Aetna* from continuing to violate Section  
 5 1557. Compl., Prayer for Relief ¶¶A-D.<sup>12</sup> Encore is not necessary for either form of relief.

6 First, Plaintiff seeks damages for Aetna’s independent violations of Section 1557, not  
 7 payment of benefits under the Plan. *See id.* ¶¶100–01, Prayer for Relief ¶¶C–D; *see, e.g., Tovar*  
 8 *v. Essentia Health*, 857 F.3d 771, 778 (8th Cir. 2017) (out-of-pocket medical expenses are  
 9 “traceable to and redressable through damages” from TPA defendants); *Tovar*, 342 F.Supp.3d at  
 10 953–54, 956 (TPA liable for damages to plaintiff for being “denied access and receiving delayed  
 11 access to medically necessary care”). There is no question that Plaintiff and the putative class  
 12 may obtain complete relief as to Aetna without Encore, even if Encore might also be liable for  
 13 discrimination. *See Disabled Rts.*, 375 F.3d at 879 (complete relief “is concerned with  
 14 consummate rather than partial or hollow relief *as to those already parties*”) (emphasis added);  
 15 *Ward*, 791 F.3d at 1048 (“It has long been the rule that it is not necessary for all joint tortfeasors  
 16 to be named as defendants in a single lawsuit.”) (quoting *Temple v. Synthes Corp.*, 498 U.S. 5, 7  
 17 (1990) (per curiam)); *cf. Lewis v. Clarke*, 581 U.S. 155, 167 (2017) (“a party does not become a  
 18 required party... under [Rule] 19 simply by virtue of indemnifying one of the named parties”).

19 Aetna does not deny that it is subject to Section 1557, but argues that the language of the  
 20 Master Services Agreement between itself and Encore (“MSA”) vests final responsibility for the  
 21 Plan with Encore. Mot. at 15, 16 n.14. Plaintiff, however, alleges that Aetna is responsible for  
 22 designing the discriminatory Infertility Policy and incorporating it into the Plan, and on a motion  
 23 to dismiss, Plaintiff’s allegations must be accepted as true. *See* Compl. ¶¶21–26, 52–62; *Paiute-*  
 24 *Shoshone Indians*, 637 F.3d at 996 n.1; *Carr v. United Healthcare Servs. Inc.*, No. C15-1105-  
 25 MJP, 2016 WL 7716060, at \*3–4 (W.D. Wash. May 31, 2016) (rejecting TPA’s argument on

26  
 27 <sup>12</sup> “[P]rivate plaintiffs may secure injunctive or monetary relief’ under Spending Clause statutes  
 28 that prohibit discrimination, including Section 1557. *Cummings v. Premier Rehab Keller*,  
*P.L.L.C.*, 142 S.Ct. 1562, 1568, 1571 (2022).

1 motion to dismiss that it had no control over plan, which controverted plaintiff’s allegations).<sup>13</sup>  
2 Every court to consider the issue has held that, by its plain terms, Section 1557 subjects TPAs to  
3 liability for discriminatory benefit design in self-funded plans, even if the plan sponsor may also  
4 be liable. *See Tovar*, 857 F.3d at 778 (TPAs may be liable for discriminatory benefit design  
5 where the plan terms “originated with” the TPA, even if the plan sponsor “subsequently adopted  
6 the plan and maintained control over its terms”); *Tovar*, 342 F.Supp.3d at 954 (same); *Pritchard*,  
7 2022 WL 17788148, at \*6 (similar).

8 Further, even if the discriminatory plan terms did not originate with Aetna and its  
9 Infertility Policy, as Plaintiff alleges, Aetna is still liable under Section 1557 for its voluntarily  
10 undertaken role as a TPA in administering and enforcing discriminatory coverage terms. *See*  
11 Compl. ¶¶52–63. Aetna is no helpless bystander. Aetna voluntarily decided to disregard its legal  
12 obligations under Section 1557 and administer and enforce plan terms that discriminate against  
13 LGBTQ individuals. *See Pritchard*, 2022 WL 17788148, at \*8–9 (“[W]hether Blue Cross  
14 provided the Exclusionary language or not is immaterial because Blue Cross has an independent  
15 duty to comply with Section 1557.”). Regardless of whether the discriminatory Plan design  
16 originated with Aetna, Plaintiff has stated a Section 1557 claim against Aetna, and Encore is not  
17 necessary to afford Plaintiff and the putative class the damages they seek.

18 Second, the declaratory and injunctive relief Plaintiff seeks is specifically and narrowly  
19 targeted at enjoining only *Aetna’s* actions. Plaintiff seeks a declaration that Aetna “violated  
20 Plaintiff’s and the Classes’ rights under Section 1557 of the ACA by virtue of its discriminatory  
21 Infertility Policy ...,” Compl. ¶102, Prayer for Relief ¶A, and an injunction enjoining “[Aetna]  
22 from implementing and enforcing Aetna’s discriminatory Infertility Policy and from designing,  
23 marketing, selling, supplying, issuing, underwriting, or administering plans that include,  
24

---

25 <sup>13</sup> Aetna implies that its Infertility Policy merely “tracked the definition of infertility in the  
26 Encore Plan,” Mot. at 5, rather than the other way around, as Plaintiff alleges. But nothing in the  
27 record contravenes Plaintiff’s allegation that Aetna is the origin of the content of the Infertility  
28 Policy, and it strains credulity to suggest that Aetna’s Infertility Policy—which is on its website  
and applies broadly to Aetna-administered plans nationwide, *see* Chan Decl. ¶2 & Exh. A—in  
fact derived from a definition of infertility originating with Encore, just one of Aetna’s  
innumerable self-insured customers.

1 incorporate, or rely on any policy that denies equal fertility treatment coverage to individuals  
 2 who cannot become pregnant through sexual intercourse with their partner because of sexual  
 3 orientation or gender identity,” *id.*, Prayer for Relief ¶B. None of this relief requires Encore’s  
 4 cooperation, and Plaintiff does not seek to enjoin Encore or reform the terms of the Plan. *See*  
 5 *Carr*, 2016 WL 7716060, at \*1, 4 (plan sponsor not necessary where plaintiff “crafted her relief  
 6 request such that she may obtain the relief she requests without [the plan sponsor] as a party”).  
 7 Mere speculation that Aetna, if so enjoined, may choose to terminate its MSA with Encore, or  
 8 that Encore may choose to terminate the MSA and seek out a different TPA willing to administer  
 9 discriminatory plan terms, does not make the requested relief against Aetna “partial or hollow.”  
 10 *Disabled Rts.*, 375 F.3d at 879–80 (possibility that defendant may choose to breach its contract  
 11 with absent party to comply with injunction did not render absent party necessary); *Physics,*  
 12 *Materials & Applied Mathematics Rsch. LLC v. Yeak*, No. CV-20-00379-TUC-JCH, 2022 WL  
 13 3286585, at \*5 (D. Ariz. Aug. 11, 2022) (similar); *see Salt River Project Agr. Imp. & Power*  
 14 *Dist. v. Lee*, 672 F.3d 1176, 1180 (9th Cir. 2012) (“possibility” that future officials could seek to  
 15 enforce challenged policy “does not mean that complete relief is not possible for the plaintiffs,  
 16 who seek to enjoin only the named defendants [i.e., current officials]”; “[i]f in the future the  
 17 plaintiffs believe that other officials are acting in violation of federal law, they may bring another  
 18 action against those officials”).

19 **2. Encore Has Not Claimed Any Interest in This Litigation, Nor Has Aetna**  
 20 **Identified Any Legally Protected Interest Encore Could Claim.**

21 Aetna also argues that Encore is a necessary party under Rule 19(a)(1)(B) because  
 22 “proceeding without Encore ‘may ... as a practical matter impair or impede [its] ability to  
 23 protect’ its legal interests.” Mot. at 15.<sup>14</sup> But Aetna entirely ignores the “initial requirement” for  
 24 compulsory joinder under Rule 19(a)(1)(B), namely, “that the absent party *claim* a legally  
 25 protected interest relating to the subject matter of the action.” *Bowen*, 172 F.3d at 689 (quotation

26 \_\_\_\_\_  
 27 <sup>14</sup> Aetna does not argue that failure to join Encore could expose Aetna, an “existing party” in the  
 28 case, “to a substantial risk of incurring double, multiple, or otherwise inconsistent obligations  
 because of the interest.” Fed. R. Civ. P. 19(a)(1)(B)(ii). Any such argument Aetna may try to  
 make on reply is thus waived.

1 marks and citation omitted; emphasis in original); *see also Northrop Corp. v. McDonnell*  
 2 *Douglas Corp.*, 705 F.2d 1030, 1043–44 (9th Cir. 1983) (absent party not “necessary” in part  
 3 because it “never asserted a formal interest in either the subject matter of this action or the action  
 4 itself”). Aetna offers no evidence that *Encore* itself has claimed an interest here. *Encore*’s failure  
 5 to assert an interest precludes any argument that it is a necessary party to this action under Rule  
 6 19(a)(1)(B). *See, e.g., Roberts v. City of Fairbanks*, 947 F.3d 1191, 1204 (9th Cir. 2020).<sup>15</sup>

7 In any event, the interests Aetna improperly attempts to assert on *Encore*’s behalf are not  
 8 “legally protected” interests entitled to protection under Rule 19. To be legally protected, the  
 9 claimed interest must “be more than a financial stake, and more than speculation about a future  
 10 event.” *See Makah Indian Tribe*, 910 F.2d at 558. This question “normally involves an inquiry  
 11 into the possibility of the absent party being collaterally estopped in another proceeding.” *U.S. ex*  
 12 *rel. Morongo Band of Mission Indians v. Rose*, 34 F.3d 901, 908 (9th Cir. 1994).

13 Aetna asserts that “*Encore* faces the risk of follow-on litigation based on rulings in this  
 14 case.” Mot. at 18. But this risk is no different than the interest *Encore* might have in a different  
 15 case asserting Section 1557 claims against a different health insurer or TPA alleging that terms  
 16 similar to those in the *Encore* Plan are facially discriminatory. *Encore* is not in privity with  
 17 Aetna, and any judgment against Aetna in this case will have no preclusive effect on *Encore*. *See*  
 18 *Ward*, 791 F.3d at 1054 (no legally protected interest where absent party “will not be bound [in  
 19 subsequent proceedings] by the district court’s interpretation” of absent party’s contract with  
 20 consumers) (citing *Blonder-Tongue Labs., Inc. v. Univ. of Ill. Found.*, 402 U.S. 313, 329 (1971)).  
 21 Indeed, adjudicating Aetna’s liability under Section 1557 will not require adjudicating the  
 22 entirely separate issue of whether *Encore* (which Plaintiff has no reason to believe, and which  
 23 Aetna has not suggested, is subject to Section 1557) may lawfully offer its employees an ERISA  
 24  
 25

26 \_\_\_\_\_  
 27 <sup>15</sup> *See also, e.g., Physics, Materials & Applied Mathematics Rsch*, 2022 WL 3286585, at \*6–7  
 28 (United States not a necessary party where “no evidence” it had claimed an interest); *Almont*  
*Ambulatory Surgery Ctr., LLC v. UnitedHealth Grp., Inc.*, No. CV 14-3053-MWF (AFMx),  
 2018 WL 11241771, at \*12–13 (C.D. Cal. Apr. 11, 2018) (denying Rule 12(b)(7) motion).

1 benefits plan that discriminates on the basis of sex.<sup>16</sup> The mere risk of follow-on litigation—in  
 2 which Encore will have an opportunity to defend itself—is not the type of interest Rule 19  
 3 protects.<sup>17</sup>

4 Aetna’s reliance on cases holding that parties to a contract are necessary to an action  
 5 seeking to set aside that contract is likewise misplaced. *See* Mot. at 17–18. This suit “is not ‘an  
 6 action to set aside ... a contract.’” *Disabled Rts.*, 375 F.3d at 881 (quoting *Dawavendewa v. Salt*  
 7 *River Project Agr. Imp. & Power Dist.*, 276 F.3d 1150, 1156 (9th Cir. 2002)). Rather, it is an  
 8 action to enforce Aetna’s compliance with Section 1557. As in *Disabled Rights*, nothing in the  
 9 MSA between Aetna and Encore “requires discrimination on the basis of” sex. *See* 375 F.3d at  
 10 881. To the contrary, the MSA allows for [REDACTED]

11 [REDACTED]  
 12 [REDACTED]” Dkt. 40-2, Exh.  
 13 A to the Decl. of Robert Goldbeck, MSA §23.02(C). The possibility that an element of the  
 14 Agreement could be deemed unlawful was clearly anticipated by both Encore and Aetna.<sup>18</sup>

15 Even if Aetna were to terminate its agreement with Encore (which it need not do to  
 16 comply with Plaintiff’s requested injunction), and even if Encore were unable to find another  
 17 TPA for its plan, that outcome implicates only a financial interest, which the Ninth Circuit has

18 \_\_\_\_\_  
 19 <sup>16</sup> In *Disabled Rts.*, 375 F.3d at 865–67, the plaintiff sued two private entities that staged a rodeo  
 20 at a publicly owned arena for violations of Title III of the Americans with Disabilities Act  
 21 (“ADA”). 375 F.3d at 865–67. Defendants argued that the University System lessor was a  
 22 necessary party because “judgment in *Disabled Rights*’ favor would amount to a declaration that  
 23 University System is operating a facility in violation of the ADA.” *Id.* at 882. The Ninth Circuit  
 24 rejected this argument, noting that the University System and private entity defendants were  
 25 subject to different statutory provisions: “As their respective statutory obligations are not  
 26 identical, University System is not a necessary party to an adjudication of the extent of the  
 27 private defendants’ compliance with Title III.” *Id.* at 882–83.

28 <sup>17</sup> *Hammons v. Wells Fargo Bank, N.A.*, No. 15-CV-04897-RS, 2015 WL 9258092, at \*7 (N.D.  
 Cal. Dec. 18, 2015) and *Weiss v. Perez*, 602 F.Supp.3d 1279, 1294 (N.D. Cal. 2022) do not  
 support Aetna’s argument. Both cases discussed the risk that *defendant*, an existing party, could  
 face subsequent litigation subjecting it to the risk of “incurring multiple obligations,” rendering  
 the absent party necessary under Rule 19(a)(1)(B)(ii). Aetna has made no such argument here.  
*See supra* at 18 n.14.

<sup>18</sup> If Plaintiff prevails on her Section 1557 claim against Aetna, only a portion of the MSA will  
 be affected—the obligation to comply with Aetna’s discriminatory Infertility Policy and deny  
 claims for fertility coverage made by plan members in LGBTQ relationships. The contract as a  
 whole need not be terminated. *See* MSA §23.02(C).

1 squarely held is insufficient to establish a “legally protected interest” for purposes of Section  
 2 19(a)(2). *See Disabled Rts.*, 375 F.3d at 883 (possibility that “a judgment against Events or  
 3 Cowboys could dissuade other private entities subject to Title III from entering into agreements  
 4 with University System for use of the Center” and that “University System stands to lose a  
 5 valuable source of income” did not give rise to “legally protected interest”).<sup>19</sup>

6 Because Encore is not a necessary party under Rule 19(a)(1), the Court should deny  
 7 Aetna’s motion “at step one.” *See Alto*, 738 F.3d at 1126; *Disabled Rts.*, 375 F.3d at 883.<sup>20</sup>

8 **B. Even If Encore Were a Necessary Party, Dismissal Would Be Improper Because**  
 9 **Encore Can Feasibly Be Joined.**

10 Even if Aetna had carried its burden of showing that Encore is necessary under Rule  
 11 19(a), the proper result would be to order joinder, not dismissal, because the Court plainly has  
 12 personal jurisdiction over Encore, and venue in this District is proper. Under California’s long-  
 13 arm statute, which is coextensive with federal due process requirements, a court may exercise  
 14 specific personal jurisdiction over a non-resident defendant if (1) the defendant “purposefully  
 15 direct[s] his activities” at “the forum or resident thereof,” or “purposefully avails himself of the  
 16 privilege of conducting activities in the forum”; (2) the claim “arises out of or relates to the  
 17 defendant’s forum-related activities”; and (3) the exercise of jurisdiction “comport[s] with fair  
 18 play and substantial justice.” *Schwarzenegger v. Fred Martin Motor Co.*, 374 F.3d 797, 800–02

19 <sup>19</sup> Aetna argues not only that this financial interest renders Encore a necessary party, but also that  
 20 *every* plan sponsor has the same interest that “would equally be implicated” by an injunction  
 21 prohibiting Aetna from enforcing its Infertility Policy. Mot. at 16 n.14. Not only is this class  
 22 certification argument premature on a motion to dismiss, but it is a misconstruction of Rule 19  
 23 that could in practice allow any defendant to avoid class-wide liability—even for a written policy  
 24 that violates federal law—by entering into enough contracts agreeing to apply the illegal policy  
 25 to make joinder impossible. This absurd result reinforces the conclusion that the financial interest  
 26 Encore has here is not the type of protected interest covered by Rule 19.

27 <sup>20</sup> Aetna’s contention that “this case is similar to *Takeda v. Northwestern National Life Insurance*  
 28 *Co.*, 765 F.2d 815 (9th Cir. 1985),” Mot. at 18, is far-fetched. In *Takeda*, the plan sponsor was  
 deemed a necessary party because the plaintiff sought payment of benefits under the plan, it was  
 “not clear” from plaintiff’s allegations whether the plan sponsor or the claims administrator  
 “made the decisions about which plaintiffs complain,” the plan sponsor claimed an interest in the  
 case, and the two parties were “sufficiently close” as to create a significant risk of collateral  
 estoppel. *Id.* at 819–21. Here, Plaintiff is not seeking plan benefits, she has expressly alleged that  
 Aetna is responsible for designing the discriminatory Policy under Section 1557, Encore has not  
 asserted *any* interest in this case, and Aetna has made no argument that it is in privity with  
 Encore; indeed, Aetna asserts not that Encore should be *joined* to this action if feasible but that it  
 should be *substituted* for Aetna. *See* Mot. at 16 n.14.

1 (9th Cir. 2004) (citation omitted); *see* Fed. R. Civ. P. 4(k)(1)(A).

2 All three jurisdictional requirements are met here. If required to join Encore, Plaintiff will  
 3 be able to establish that Encore employs Plaintiff’s wife in California and has a designated agent  
 4 for service of process in California registered with the California Secretary of State, thereby  
 5 purposefully availing itself of the privilege of conducting business in California. Chan Decl.  
 6 ¶¶3–4; *see, e.g., Mewawalla v. Middleman*, 601 F.Supp.3d 574, 595 (N.D. Cal. 2022) (citing  
 7 cases). Plaintiff’s Section 1557 claim against Aetna arises from the Plan to which she is a  
 8 beneficiary by virtue of her wife’s employment by Encore in California, thereby arising from  
 9 Encore’s California-related activities. Compl. ¶¶13, 52–53. Where a plaintiff’s claim arises from  
 10 a defendant’s activities purposefully directed to California, the exercise of jurisdiction is  
 11 presumptively reasonable and comports with fair play and substantial justice. *See Sher v.*  
 12 *Johnson*, 911 F.2d 1357, 1364–65 (9th Cir. 1990).<sup>21</sup> And because “a substantial part of the acts  
 13 complained of occurred in the Northern District of California,” Compl. ¶11, venue in this District  
 14 is likewise proper. *See* 28 U.S.C. §1391(b)(2).<sup>22</sup> Accordingly, if the Court were to determine that  
 15 Encore is a necessary party for any reason, the proper result would be to order joinder of Encore,  
 16 not to dismiss the case. *See* Fed. R. Civ. P. 19(a)(2).<sup>23</sup>

17 **C. Even If Joinder of Encore Were Not Feasible, Equity and Good Conscience**  
 18 **Preclude Dismissal Under Rule 19(b).**

19 Even if it were not feasible to join Encore, “equity and good conscience” would render it  
 20 improper to dismiss this action under Rule 19(b). The Rule 19(b) inquiry “is a practical one and  
 21 fact specific ... and is designed to avoid the harsh results of rigid application.” *Makah Indian*  
 22 *Tribe*, 910 F.2d at 558. Courts balance: “(1) prejudice to any party or to the absent party; (2)

23 \_\_\_\_\_  
 24 <sup>21</sup> Because all requirements for specific personal jurisdiction are satisfied, it is irrelevant whether  
 25 “Encore is registered in Delaware and maintains its primary office in Illinois” and the “Encore  
 26 Plan was created in Illinois”—facts that Aetna simply asserts without evidence. Mot. at 15–16.

26 <sup>22</sup> Aetna cites a provision in the MSA between Encore and Aetna specifying “that ‘sole and  
 27 exclusive venue’ shall lie in Delaware,” Mot. at 16, but that provision is inapplicable to Plaintiff,  
 28 who is not a party to the MSA and is not asserting any rights thereunder.

27 <sup>23</sup> At minimum, if there is any doubt, Plaintiff should be granted leave to amend her complaint to  
 28 allege facts establishing personal jurisdiction over Encore. *See, e.g., Wilson v. Metals USA, Inc.*,  
 No. CIV S-12-0568 LKK, 2012 WL 5932990, at \*9–10 (E.D. Cal. Nov. 27, 2012).

1 whether relief can be shaped to lessen prejudice; (3) whether an adequate remedy, even if not  
2 complete, can be awarded without the absent party; and (4) whether there exists an alternative  
3 forum.” *Kescoli v. Babbitt*, 101 F.3d 1304, 1310–11 (9th Cir. 1996); *see* Fed. R. Civ. P. 19(b).

4 Here, the factors weigh heavily against dismissal. The first factor is largely duplicative of  
5 Rule 19(a)(1)(B)(i). *Am. Greyhound Racing, Inc. v. Hull*, 305 F.3d 1015, 1024–25 (9th Cir.  
6 2002). As explained, this is a civil rights lawsuit, not an ERISA action seeking to recover plan  
7 benefits, and Encore has not asserted any legally protected interests in this litigation that would  
8 be prejudiced by nonjoinder. *See supra* at 16. Aetna’s ERISA cases, none of which involve  
9 claims under Section 1557 or analogous statutes, are thus inapposite.<sup>24</sup> Nor is this an action to  
10 “set aside a contract,” *see supra* at 20, and Aetna’s reliance on contracts cases is likewise  
11 misplaced.<sup>25</sup> The second and third factors also weigh against dismissal, because to the extent any  
12 portion of the injunctive relief Plaintiff seeks could be construed as impacting Encore’s legally  
13 protected interests, any injunction could be shaped to lessen such prejudice. *See Makah Indian*  
14 *Tribe*, 910 F.2d at 560 (“The Supreme Court has encouraged shaping relief to avoid dismissal.”)  
15 (citing *Provident Tradesmens Bank & Tr. Co. v. Patterson*, 390 U.S. 102, 111–12 (1968)).

16 Finally, Aetna offers no alternative forum, arguing that this case must be dismissed entirely; this  
17  
18

---

19 <sup>24</sup> *See Sypher v. Aetna Ins. Co.*, No. 13-10007, 2014 WL 1230028, at \*1, 4 (E.D. Mich. Mar. 25,  
20 2014) (“an ERISA case ... seeking payment of long-term disability benefits”); *Cuevas v. Joint*  
21 *Benefit Tr.*, No. 13-CV-00045-JST, 2013 WL 3578496, at \*1 (N.D. Cal. July 12, 2013)  
22 (involving an “action for violations of ERISA”); *Almont Ambulatory Surgery Ctr., LLC v.*  
23 *UnitedHealth Grp., Inc.*, 99 F.Supp.3d 1110 (C.D. Cal. 2015) (holding that plaintiffs bringing  
24 ERISA claims may properly sue the plan or plan administrators, among other defendants); *cf. In*  
25 *re Lowenschuss*, 171 F.3d 673, 677 (9th Cir. 1999) (holding pension plan trustee could intervene  
26 in bankruptcy action that implicated whether the plan was ERISA-qualified at all). *Baird v.*  
27 *Blackrock Institutional Tr. Co., N.A.*, No. 17-CV-01892-HSG, 2020 WL 7389772 (N.D. Cal.  
28 Feb. 11, 2020), another ERISA case, is also readily distinguishable. There, plaintiffs’ breach-of-  
fiduciary-duty claims turned on the reasonableness of different fee structures defendant  
independently negotiated with each plan fiduciary, thus defeating class certification. *Id.* at \*5,  
\*10–12. Here, whether Aetna’s Policy facially discriminates in violation of Section 1557 does  
not depend on any underlying negotiations with Encore, and in any event Plaintiff alleges Aetna  
incorporates the Policy by default into plans, without independent negotiation. Compl. ¶¶22, 26.

<sup>25</sup> *See Lomayaktewa v. Hathaway*, 520 F.2d 1324, 1325 (9th Cir. 1975) (an action “to void [a]  
lease”); *Kermanshah v. Kermanshah*, No. 08-CV-409, 2010 WL 1904135, at \*3 (S.D.N.Y. May  
11, 2010) (holding all parties to a contract necessary to an action by plaintiff—one contracting  
party—seeking to enjoin any reduction in his interests under the contract).



1 factor, too, weighs strongly against dismissal. *See id.*<sup>26</sup>

2 Dismissal would also be improper because this action falls within the “public rights”  
3 exception to joinder. *See Conner v. Burford*, 848 F.2d 1441, 1459 (9th Cir. 1998). Under that  
4 doctrine, a necessary party will not be deemed “indispensable” if (1) the litigation “transcend[s]  
5 the private interests of the litigants and seek[s] to vindicate a public right” and (2) the litigation  
6 does “not destroy the legal entitlements of the absent parties,” even if it “may adversely affect  
7 the absent parties’ interests.” *Kescoli*, 101 F.3d at 1311 (quotation marks omitted); *see, e.g.*,  
8 *Conner*, 848 F.2d at 1442, 1460-61 (third-party lessees not indispensable to action seeking  
9 compliance with National Environmental Policy Act and Endangered Species Act in particular  
10 leases, even though injunction requiring compliance might deprive them of their right to specific  
11 performance or create delays in implementation, because contracts themselves “were not  
12 invalidated and further actions construing rights under them [were] not precluded”). The public  
13 interest exception applies here because Plaintiff is seeking to vindicate a public right to “access  
14 to and coverage of health care in a nondiscriminatory manner” under Section 1557. *Notice of*  
15 *Proposed Rulemaking, Nondiscrimination in Health Programs and Activities*, 87 Fed. Reg.  
16 47,824, 47,825 (Aug. 4, 2022). This action will also not destroy Encore’s rights. Even if an  
17 injunction against Aetna did affect administration of the Plan, it would not invalidate any  
18 contracts or destroy Encore’s ability to assert its rights vis-à-vis Aetna under the MSA.

### 19 **III. ERISA Does Not Preempt Plaintiff’s Section 1557 Claim.**

20 Aetna’s argument that Plaintiff’s Section 1557 claim is barred by §302 of ERISA  
21 (codified at 29 U.S.C. §1132(a)(1)(B)) ignores that ERISA *does not preempt other federal*  
22 *claims*. ERISA’s text expressly provides that “[n]othing in this subchapter shall be construed to  
23 alter, amend, modify, invalidate, impair, or supersede any law of the United States ....” 29  
24 U.S.C. §1144(d). Accordingly, as multiple courts have held, ERISA does not preempt Section  
25 1557 claims. *See, e.g., Pritchard*, 2022 WL 17788148, at \*8 (requirement under ERISA that a  
26 TPA “make decisions in ‘accordance with the documents and instruments governing the plan,’  
27

28 <sup>26</sup> The *Takeda* court relied on the availability of state court as an alternative forum, 765 F.2d at 821, whereas here the claims are solely federal.

29 U.S.C. §1104(a)(1)(D), ... must not be construed to ‘invalidate or impair’ Section 1557, 29 U.S.C. §1144(d).”); *Scott v. St. Louis Univ. Hosp.*, 600 F.Supp.3d 956, 960 (E.D. Mo. 2022); *Tovar*, 342 F.Supp.3d at 954 (“The Court will not construe ERISA to impair Section 1557.”).<sup>27</sup>

Aetna tries to distinguish these cases by misconstruing Plaintiff’s claim as seeking to recover under the Plan, rather than challenging a discriminatory policy. *See* Mot. at 20. Again, Plaintiff does not contend that Aetna incorrectly administered the Plan, nor is Plaintiff seeking to recover benefits. Rather, Plaintiff claims that Aetna’s definition of infertility denies her and other class members equal access to “coverage for fertility treatments [that would] *otherwise* [be] covered by their plans” but for their or their partner’s sexual orientation or gender identity, in violation of Section 1557. Compl. ¶27 (emphasis added).<sup>28</sup> That claim is not ERISA-preempted.

#### **IV. Defendants’ Attempt to Dismiss Aetna Inc. Under Rule 12(b)(6) Is Improper.**

Aetna Inc. seeks dismissal based entirely on extraneous material not properly considered under Rule 12(b)(6). *See* Mot. at 20-21; *Khoja*, 899 F.3d at 998.<sup>29</sup> Plaintiff’s allegations are all pled jointly against both Defendants. *See* Compl. ¶¶1, 52. Plaintiff states a claim against both. *See Taylor v. Accredited Home Lenders, Inc.*, 580 F.Supp.2d 1062, 1070-71 (S.D. Cal. 2008).

### **CONCLUSION**

For all the foregoing reasons, Aetna’s motion to dismiss should be denied.

<sup>27</sup> Aetna cites no case holding that a *federal* claim, like Section 1557, is ERISA-preempted. Both *Pilot Life Ins. Co. v. Dedeaux*, 481 U.S. 41, 42–43 (1987) and *Lea v. Republic Airlines, Inc.*, 903 F.2d 624, 633 (9th Cir. 1990) addressed only preemption of state common law claims. *See* Mot. at 19. And in quoting *Aetna Health Inc. v. Davila*, 542 U.S. 200 (2004), Aetna omits that the full sentence reads: “[A]ny *state-law cause of action* that duplicates, supplements, or supplants the ERISA civil enforcement remedy conflicts with the clear congressional intent to make the ERISA remedy exclusive and is therefore pre-empted.” 542 U.S. at 209 (emphasis added).

<sup>28</sup> Even if Plaintiff *were* seeking to recover benefits under the plan (and if other federal law claims could be preempted by ERISA, which they cannot), her claim would still survive. Even state law claims are not preempted by Section 502 unless “there is no other independent legal duty that is implicated by a defendant’s actions.” *Fossen v. Blue Cross & Blue Shield of Mont., Inc.*, 660 F.3d 1102, 1107 (9th Cir. 2011). Aetna cannot meet that standard—and notably does not even attempt to do so—as Section 1557 creates such an independent legal duty on Aetna.

<sup>29</sup> Plaintiff moves to strike the Declaration of Craig Alloca. *See, e.g., City of Royal Oak Retirement Sys. v. Juniper Networks, Inc.*, 880 F.Supp.2d 1045, 1060 (N.D. Cal. 2012) (striking extraneous declarations). At minimum, if the Court were to consider the Alloca Declaration and convert Aetna’s motion into one for summary judgment, Plaintiff should be granted an opportunity to take discovery before the Court rules. *See* Fed. R. Civ. P. 56(d).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Respectfully submitted,

Dated: September 1, 2023

ALTSHULER BERZON LLP  
Barbara J. Chisholm  
Danielle E. Leonard  
Connie K. Chan  
Robin S. Tholin

LIU PETERSON-FISHER LLP  
Rebecca Peterson-Fisher  
Jennifer L. Liu  
C. Leah Kennedy

NATIONAL WOMEN’S LAW CENTER  
Michelle Banker (admitted *pro hac vice*)  
Alison Tanner (admitted *pro hac vice*)  
Noel León (admitted *pro hac vice*)  
Sudria Twyman (admitted *pro hac vice*)

By: /s/ Connie K. Chan  
Connie K. Chan

*Attorneys for Plaintiff and the Putative Class*

1 Rebecca Peterson-Fisher (SBN 255359)  
 2 Jennifer L. Liu (SBN 279370)  
 3 C. Leah Kennedy (SBN 346306)  
**LIU PETERSON-FISHER LLP**  
 4 1204 Burlingame Ave., Suite 3  
 Burlingame, CA 94010  
 5 Tel: 650.461.9000  
 Fax: 650.460.6967  
 6 Email: rpf@liupetersonfisher.com  
 jliu@liupetersonfisher.com  
 lkennedy@liupetersonfisher.com

7  
 8 Barbara J. Chisholm (SBN 224656)  
 Danielle E. Leonard (SBN 208201)  
 9 Connie K. Chan (SBN 284230)  
 Robin S. Tholin (SBN 344845)  
 10 **ALTSHULER BERZON LLP**  
 11 177 Post Street, Suite 300  
 San Francisco, CA 94108  
 12 Tel: 415.421.7151  
 Fax: 415.362.8064  
 13 E-mail: bchisholm@altshulerberzon.com  
 dleonard@altshulerberzon.com  
 14 cchan@altshulerberzon.com  
 rtholin@altshulerberzon.com

Michelle Banker (admitted *pro hac vice*)  
 Alison Tanner (admitted *pro hac vice*)  
 Noel León (admitted *pro hac vice*)  
 Sudria Twyman (admitted *pro hac vice*)  
**NATIONAL WOMEN’S LAW CENTER**  
 1350 I Street NW, Suite 700  
 Washington, DC 20005  
 Tel: 202.588.5180  
 Email: mbanker@nwlc.org  
 atanner@nwlc.org  
 nleon@nwlc.org  
 stwyman@nwlc.org

15  
16  
17 *Attorneys for Plaintiff and the Putative Class*

18 UNITED STATES DISTRICT COURT  
 19 NORTHERN DISTRICT OF CALIFORNIA  
 20 OAKLAND DIVISION

21 MARA BERTON, on behalf of herself and  
22 all others similarly situated,

23 Plaintiff,

24 v.

25 AETNA INC. and AETNA LIFE  
26 INSURANCE COMPANY,

27 Defendants.  
28

CASE NO.: 4:23-cv-01849-HSG

**DECLARATION OF CONNIE K. CHAN  
IN SUPPORT OF PLAINTIFF’S  
OPPOSITION TO DEFENDANTS’  
MOTION TO DISMISS**

1 **DECLARATION OF CONNIE K. CHAN**

2 I, Connie K. Chan, hereby declare as follows:

3 1. I am an attorney at the law firm of Altshuler Berzon LLP, counsel of record for  
4 Plaintiff Mara Berton and the putative class in this action. I submit this declaration in support of  
5 Plaintiff's Opposition to Defendants Aetna Inc. and Aetna Life Insurance Company's ("Aetna"  
6 or "Defendants") Motion to Dismiss Complaint. I have personal knowledge of the facts set forth  
7 below and if called as a witness in this action, could and would testify competently thereto.


8 2. Aetna publishes its Clinical Policy Bulletin No. 0327—Infertility ("Infertility  
9 Policy") on its website at [https://www.aetna.com/cpb/medical/data/300\\_399/0327.html](https://www.aetna.com/cpb/medical/data/300_399/0327.html). The  
10 version that is currently available on Aetna's website at this link indicates that it was last revised  
11 August 10, 2023. On August 31, 2023, an attorney at my firm used Archive.org's "Wayback  
12 Machine" to access and screenshot a cached version of the Infertility Policy that was available at  
13 this link on April 1, 2023. *See EVO Brands, LLC v. Al Khalifa Grp., LLC*, --F.Supp.3d--, 2023  
14 WL 26768743, at \*4 (C.D. Cal. Feb. 23, 2023) (explaining that the Wayback Machine "captures  
15 and preserves snapshots of a website's state at specific time intervals"). This version of Aetna's  
16 Policy indicates that it was last revised January 20, 2023, and is the version referenced in  
17 paragraph 30 of Plaintiff's Complaint. Attached hereto as **Exhibit A** is a true and correct copy of  
18 an excerpt of the January 2023 version of the Policy, as captured by the Wayback Machine on  
19 April 1, 2023.

20 3. Attached hereto as **Exhibit B** is a true and correct copy of Encore Group (USA)  
21 LLC's ("Encore") Statement of Information (Form LLC-12) dated January 11, 2022 and filed  
22 with the California Secretary of State, which I downloaded September 1, 2023 from the  
23 California Secretary of State's website using the Business Search function at  
24 <https://bizfileonline.sos.ca.gov/search/business>. According to Encore's Form LLC-12 and the  
25 California Secretary of State's website, Encore is listed in active status and in good standing with  
26 the California Secretary of State, and has designated CT Corporation System as its registered  
27

1 agent for service of process in California, with a service address of 330 N. Brand Blvd, Glendale,  
2 CA.

3 4. Plaintiff's wife June Higginbotham is and has at all relevant times been employed  
4 by Encore in California. If necessary, Plaintiff could and would amend her complaint to so state.

5 I declare under penalty of perjury under the laws of the State of California and the United  
6 States that the foregoing is true and correct. Executed this 1st day of September 2023 in  
7 Burlingame, California.

8  
9   
10 \_\_\_\_\_  
11 Connie K. Chan

# **EXHIBIT A**

-->

The Wayback Machine - [https://web.archive.org/web/20230401084153/https://www.aetna.com/cpb/medical/data/300\\_399/0327.html](https://web.archive.org/web/20230401084153/https://www.aetna.com/cpb/medical/data/300_399/0327.html)



[\(https://web.archive.org/web/20230401084153/https://www.aetna.com/\)](https://web.archive.org/web/20230401084153/https://www.aetna.com/)

# Infertility

[Clinical Policy Bulletins](#) | [Medical Clinical Policy Bulletins](#)

**Number: 0327**

## Table Of Contents

[Policy](#)

[Applicable CPT / HCPCS / ICD-10 Codes](#)

[Background](#)

[References](#)

## Policy History

[Last Review](#)

01/20/2023

Effective: 05/20/1999

Next Review: 07/21/2023

[Review History](#)

[Definitions](#)

## Brand Selection for Medically Necessary Indications

### Follitropins

As defined in Aetna commercial policies, health care services are not medically necessary when they are more costly than alternative services that are at least as likely to produce equivalent therapeutic or diagnostic results. Follistim AQ (follitropin beta) is more costly to Aetna than other follicle-stimulating hormone (FSH) products. There is a lack of reliable evidence that Follistim AQ is superior to other lower cost FSH products for medically necessary indications. Therefore, Aetna considers Follistim

## Additional Information

[Clinical Policy Bulletin](#)

[Notes](#)

Top



AQ to be medically necessary only for members who have a contraindication, intolerance, or ineffective response to an adequate one-month trial of the available equivalent alternative Gonal-F (follitropin alfa).

## Policy

### Scope of Policy

This Clinical Policy Bulletin addresses interventions for the diagnosis and management of infertility.

**Note:** Requires Precertification:

Precertification of Cetrotide (cetorelix acetate), ganirelix acetate, Follistim AQ (follitropin beta), Gonal-F (follitropin alfa), Menopur (menotropins), Novarel (chorionic gonadotropin), Pregnyl (chorionic gonadotropin), Ovidrel (choriogonadotropin alfa), and chorionic gonadotropin is required of all Aetna participating providers and members in applicable plan designs. For precertification, call (866) 782-2779 (Commercial), or fax (860) 754-2515.

**Note:** Medical/Pharmacy Benefit Alignment of Coverage for Infertility Drugs and Procedures:

Medical necessity review of infertility drugs by Aetna Specialty Pharmacy Guideline Management may be bypassed for infertility drugs that are for use with infertility medical procedures if the infertility procedure has been approved for coverage under the member's Aetna medical benefit plan. During precertification, a medical authorization number and confirmation of the approval of the infertility procedures will be required to bypass medical necessity review by Specialty Pharmacy Guideline Management.

**Note:** Some plans may require medical necessity review of all infertility drugs by Aetna Specialty Guideline Management. Members of these

plans must undergo Specialty Pharmacy Guideline Management medical necessity review of all infertility drugs regardless of whether the drugs are for use with approved infertility medical procedures.

**Notes:**

1. For purposes of this entire policy, Aetna covers diagnostic infertility services to determine the cause of infertility and treatment only when specific coverage is provided under the terms of a member's benefits plan. All coverage is subject to the terms and conditions of the plan. The following discussion is applicable only to members whose plans cover infertility services.
2. For purposes of this policy, a person is considered infertile if unable to conceive or produce conception after 1 year of egg-sperm contact when the female attempting conception is under 35 years of age, or after 6 months egg-sperm contact when the female attempting conception is 35 years of age or older. Egg-sperm contact can be achieved by frequent sexual intercourse or through monthly cycles of timed sperm insemination (intrauterine, intracervical, or intravaginal). This definition applies to all individuals regardless of sexual orientation or the presence/availability of a reproductive partner. Infertility may also be established by the demonstration of a disease of the reproductive tract such that timed egg-sperm contact would be ineffective. (See Advance Reproductive Technology section below). Definitions of infertility may vary due to state mandates and plan customization; please check plan documents.
3. According to the American Society for Reproductive Medicine (ASRM, 2013), for purposes of determining when evaluation and treatment for infertility or recurrent pregnancy loss are appropriate, pregnancy is defined as a clinical pregnancy documented by ultrasonography or histopathologic examination.
4. Most plans exclude coverage of infertility services for persons who have had a previous sterilization procedure, including tubal sterilization and vasectomy, with or without surgical reversal, and for persons who have undergone a hysterectomy. Please check benefit plan descriptions for details. In addition, infertility services for persons who have undergone voluntary sterilization procedures are not covered because such services are not

considered treatment of disease, but the result of an elective procedure intended to prevent conception.

5. Some plans exclude coverage of infertility services using a woman's own eggs for women with poor ovarian reserve. Ovarian reserve is determined by measurement of menstrual cycle day 3 serum follicle-stimulating hormone (FSH) drawn after the normal onset of menstruation, or after progesterone induced menstruation for women who do not reliably menstruate. For women 39 years of age and older, ovarian responsiveness is determined by measurement of day 3 FSH obtained within the prior 6 months. For women who are less than 40 years of age, the day 3 FSH must be less than 19 mIU/mL in their most recent laboratory test to use their own eggs. For women 40 years of age and older, their unmedicated day 3 FSH must be less than 19 mIU/mL in all prior tests to use their own eggs. Please check benefit plan descriptions.
6. Infertility services for women 40 years of age and older with natural menopause is not covered because it is not considered medically necessary treatment of disease; natural menopause is not considered a disease. For women 40 years of age and older, their unmedicated day 3 FSH must be less than 19 mIU/mL in all prior tests to document that they are not menopausal and eligible for coverage of infertility treatment. Women who are less than 40 years of age who have a day 3 FSH greater than 19 mIU/L are considered to have the disease of premature ovarian failure (also known as premature ovarian insufficiency, primary ovarian insufficiency, or hypergonadotropic hypogonadism). For women with premature ovarian failure, advanced reproductive technology (ART) (in vitro fertilization) services are considered medically necessary until they reach 45 years of age. Women 40 years of age and older with premature ovarian failure may submit a new unmedicated D3 FSH level to utilize her own oocytes (even if she has had an elevated D3 FSH level above 40 years of age in the past). For women 40 years of and older with premature ovarian failure, the day 3 FSH must be less than 19 mIU/mL in their most recent laboratory test to use their own eggs. Please check benefit plan descriptions.
7. Infertility services are considered not medically necessary once pregnancy is established and a fetal heartbeat is detected.

Infertility services beyond 8 weeks of pregnancy are not considered medically necessary.

## I. Medical Necessity

### A. Females: Basic Infertility Services

The following services are considered medically necessary for diagnosis and/or treatment of infertility:

#### 1. History and Physical Examination

Basal body temperature;

#### 2. Laboratory Studies

- a. Anti-adrenal antibodies for apparently spontaneous primary ovarian insufficiency (premature ovarian failure);
- b. Anti-sperm antibodies (e.g., immunobead or mixed antiglobulin method);
- c. Chlamydia trachomatis screening (see [CPB 0433 - Chlamydia Trachomatis - Screening and Diagnosis \(/web/20230401084153/https://www.aetna.com/cpb/medical/data/400\\_499/0433.html\)](https://www.aetna.com/cpb/medical/data/400_499/0433.html));
- d. Fasting and 2 hours post 75 gram glucose challenge levels;
- e. Lipid panel (total cholesterol, HDL cholesterol, triglycerides);
- f. Post-coital testing (PCT) (Simms-Huhner test) of cervical mucus;
- g. Rubella serology;
- h. Testing for viral status (HIV, hepatitis B, hepatitis C);
- i. Serum hormone levels:
  - i. Androgens (testosterone, androstenedione, dehydroepiandrosterone sulfate (DHEA-S) if there is

evidence of hyperandrogenism (e.g., hirsutism, acne, signs of virilization) or ovulatory dysfunction;

ii. Anti-mullerian hormone (AMH), for the following indications:

- a. assessing menopausal status, including premature ovarian failure;
- b. assessing ovarian status, including ovarian reserve and ovarian responsiveness, as part of an evaluation for infertility and assisted reproduction protocols such as in vitro fertilization;

iii. Gonadotropins (serum follicle-stimulating hormone [FSH], luteinizing hormone [LH]) for women with irregular menstrual cycles (see [Appendix](#) for medical necessity limitations) or age-related ovulatory dysfunction. **Note:** Aetna considers urinary FSH testing to be experimental and investigational. Serum, not urinary, FSH is the standard of care for determination of menopausal status (AACE, 1999; NAMS, 2000; SOGC, 2002);

iv. Human chorionic gonadotrophin (hCG) (see [Appendix](#) for medical necessity limitations);

v. Prolactin for women with an ovulatory disorder, galactorrhea, or a pituitary tumor;

vi. Progestins (progesterone, 17-hydroxyprogesterone) (see [Appendix](#) for medical necessity limitations);

vii. Estrogens (estradiol) (see [Appendix](#) for medical necessity limitations);

viii. Thyroid stimulating hormone (TSH) for women with symptoms of thyroid disease;

ix. Adrenocortrophic hormone (ACTH) for ruling out Cushing's syndrome or Addison's disease in women who are amenorrheic;

x. Clomiphene citrate challenge test;

j. Karyotype testing for couples with recurrent pregnancy loss (2 or more consecutive spontaneous abortions) (see [CPB 0348 - Recurrent Pregnancy Loss \(0348.html\)](#));

### 3. Diagnostic Procedures

The following diagnostic procedures are considered medically necessary:

- a. CT or MR imaging of sella turcica is considered medically necessary if prolactin is elevated;
  - b. Endometrial biopsy;
  - c. Hysterosalpingography (hysterosalpingogram (HSG)) or hysterosalpingo-contrast-ultrasonography to screen for tubal occlusion; **Note:** Sonohysterosalpingography or saline hysterosalpingography (e.g., Femvue) are considered experimental and investigational to screen for tubal occlusion because of a lack of reliable evidence of effectiveness.
  - d. Hysteroscopy, salpingoscopy (falloscopy), hydrotubation where clinically indicated;
  - e. Laparoscopy and chromotubation (contrast dye) to assess tubal and other pelvic pathology, and to follow-up on hysterosalpingography abnormalities;
  - f. Sonohysterography to evaluate the uterus;
  - g. Ultrasound (e.g., ovarian, transvaginal, pelvic) (see [Appendix](#) for medical necessity limitations);
  - h. Monitoring of ovarian response to ovulatory stimulants:
    - i. Estradiol (see [Appendix](#) for medical necessity limitations);
    - ii. FSH (see [Appendix](#) for medical necessity limitations);
    - iii. hCG quantitative (see [Appendix](#) for medical necessity limitations);
    - iv. LH assay (see [Appendix](#) for medical necessity limitations);
    - v. Progesterone (see [Appendix](#) for medical necessity limitations);
    - vi. Serial ovarian ultrasounds are considered medically necessary for cycle monitoring (see [Appendix](#) for medical necessity limitations);
4. Non-Surgical Treatments

The following non-surgical treatments are considered medically necessary:

- a. Aromatase inhibitors (e.g., anastrozole [Arimidex], exemestane [Aromasin], and letrozole [Femara]);
- b. Corticosteroids (e.g., dexamethasone, prednisone);
- c. Estrogens (e.g., estrone and conjugated estrogens [Premarin]);
- d. Hepatitis B vaccination of partners of people with hepatitis B;
- e. Lutropin alfa (Luveris) for use in combination with human FSH to stimulate follicular development in infertile hypo-gonadotropic hypo-gonadal women or in women with a profound LH deficiency defined as LH less than 1.2 International Units/L;
- f. Metformin (Glucophage) for women with WHO Group II anovulatory disorders such as polycystic ovarian syndrome;
- g. Progestins (oral, topical gel (8 % progesterone) (Crinone 8 %, Prochieve 8 %) or intramuscular progestins and progesterone vaginal suppositories (Endometrin), see [CPB 0510 - Progestins](https://www.aetna.com/cpb/medical/data/500_599/0510.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/500\\_599/0510.html](https://www.aetna.com/cpb/medical/data/500_599/0510.html)));
- h. Prolactin inhibitors (bromocriptine (Parlodel), cabergoline (Dostinex), peroglide (Permax)) for women with ovulatory disorders due to hyperprolactinemia;
- i. Rubella vaccination of women susceptible to rubella;
- j. Tamoxifen (Novaldex) or oral clomiphene citrate (Clomid, Serophene) for ovulation induction;

**Note:** The medications listed above may not be covered for members without pharmacy benefit plans; in addition, some pharmacy benefit plans may exclude or limit coverage of some or all of these medications. Please check benefit plan descriptions for details.

## 5. Infertility Surgery

The following are considered medically necessary:

- a. Hysteroscopic adhesiolysis for women with amenorrhea who are found to have intrauterine adhesions;

- b. Hysteroscopic or fluoroscopic tubal cannulation (salpingostomy, fimbrioplasty), selective salpingography plus tubal catheterization, or transcervical balloon tuboplasty for women with proximal tubal obstruction (see [CPB 0347 - Transcervical Balloon Tuboplasty \(0347.html\)](#));
- c. Laparoscopic cystectomy for women with ovarian endometriomas;
- d. Laparoscopy for treatment of pelvic pathology;
- e. Open or laparoscopic resection, vaporization, or fulguration of endometriosis implants plus adhesiolysis in women with endometriosis;
- f. Ovarian wedge resection or ovarian drilling for women with WHO Group II ovulation disorders such as polycystic ovarian syndrome who have not responded to clomiphene citrate;
- g. Removal of myomas, uterine septa, cysts, ovarian tumors, and polyps;
- h. Surgical tubal reconstruction (unilateral or bilateral tubal microsurgery, laparoscopic tubal surgery, tuboplasty and tubal anastomosis) for women with mid or distal tubal occlusion and for women with proximal tubal disease where tubal cannulation has failed or where severe proximal tubal disease precludes the likelihood of successful cannulation;
- i. Tubal ligation (salpingectomy) for women with hydrosalpinges who are contemplating in vitro fertilization, as this has been demonstrated to improve the chance of a live birth before in-vitro fertilization treatment;
- j. Cervicectomy/trachelectomy is an acceptable alternative to hysterectomy for treatment of early stage (IA2 or small IB1) cervical adenocarcinoma in women who wish to preserve their fertility.

*B. Females: Additional Infertility Services*

The following additional services (referred to in some plans as "Comprehensive Infertility Services") may be considered medically necessary if the member is unable to conceive after



treatment with Basic Infertility Services, or if the member's diagnosis suggests that there is no reasonable chance of pregnancy as a result of Basic Infertility Services:

1. Injectable Medications

See [CPB 0020 - Injectable Medications](#)

([/web/20230401084153/https://www.aetna.com/cpb/medical/data/1\\_99/0020.html](https://web.archive.org/web/20230401084153/https://www.aetna.com/cpb/medical/data/1_99/0020.html)).

a. Gonadotropin releasing hormone analogs and antagonists - for gonadotropin-releasing hormone analogs and antagonists (GnRH; luteinizing hormone releasing hormone [LHRH]) (e.g., generic leuprolide acetate injection, leuprolide acetate for depot suspension [Lupron Depot], goserelin [Zoladex], histrelin [Supprelin LA], triptorelin [Trelstar; Triptodur], ganirelix acetate/cetrorelix acetate [Cetrotide]), see [CPB 0501 -](#)

[Gonadotropin-Releasing Hormone Analogs and Antagonists](#)

([/web/20230401084153/https://www.aetna.com/cpb/medical/data/500\\_599/0501.html](https://web.archive.org/web/20230401084153/https://www.aetna.com/cpb/medical/data/500_599/0501.html));

b. Gonadotropins:

i. Human chorionic gonadotropin (hCG) (e.g., Novarel, Pregnyl, Ovidrel, generic)

a. Criteria for Initial Approval

Aetna considers hCG medically necessary for members undergoing ovulation induction or assisted reproductive technology (ART).

Aetna considers all other indications as experimental and investigational (for additional information, see Experimental and Investigational and Background sections).

b. Continuation of Therapy

Aetna considers continuation of hCG therapy medically necessary for all members (including new members) requesting reauthorization who meet all initial authorization criteria.

ii. Menotropins for injection (Menopur)

a. Criteria for Initial Approval

Aetna considers menotropins for injection medically necessary for follicle stimulation in members undergoing ovulation induction or assisted reproductive technology (ART) who meet *any* of the following criteria:

- i. Member has completed three or more previous cycles of clomiphene; *or*
- ii. Member has a risk factor for poor ovarian response to clomiphene; *or*
- iii. Member has a contraindication or exclusion to clomiphene; *or*
- iv. Member is 37 years of age or older.

b. Continuation of Therapy

Aetna considers continuation of menotropin therapy medically necessary for all members (including new members) requesting reauthorization who meet all initial authorization criteria.

iii. Follitropins (e.g., follitropin alfa [Gonal-f]; follitropin beta [Follistim AQ])

a. Criteria for Initial Approval

Aetna considers follitropins medically necessary for the following indications when criteria are met:

Follicle stimulation - for members undergoing ovulation induction or assisted reproductive technology (ART) who meet *any* of the following criteria:

- i. Member has completed three or more previous cycles of clomiphene, *or*
  - ii. Member has a risk factor for poor ovarian response to clomiphene, *or*
  - iii. Member has a contraindication or exclusion to clomiphene, *or*
  - iv. Member is 37 years of age or older.
- b. Continuation of Therapy

Aetna considers continuation of follitropins therapy medically necessary for all members (including new members) requesting reauthorization who meet all initial authorization criteria.

**Note:** Many plans exclude coverage for infertility injectable medications; other plans may limit coverage of ovulation induction cycles with menotropins to six (6) per lifetime. Please check plan documents for details.

**Note:** Under most Aetna benefit plans, self-administered prescription medications are covered under the pharmacy benefit. Please check benefit plan descriptions.

## 2. Artificial Insemination

See [Section D](#) below

### C. Males: Infertility Services

The following services are considered medically necessary for diagnosis and/or treatment of infertility in men:

1. History and Physical Examination
2. Laboratory Studies

- a. Anti-sperm antibodies (e.g., immunobead or mixed antiglobulin method);
- b. Cultures:
  - i. Prostatic secretion;
  - ii. Semen;
  - iii. Urine;
- c. Serum hormone levels:
  - i. 17-hydroxyprogesterone;
  - ii. Adrenal cortical stimulating hormone (ACTH);
  - iii. Androgens (testosterone, free testosterone) - if initial testosterone level is low, a repeat measurement of total and free testosterone as well as serum luteinizing hormone (LH) and prolactin levels is medically necessary;
  - iv. Estrogens (e.g., estradiol, estrone);
  - v. Gonadotropins (FSH, LH);
  - vi. Growth hormone (GH);
  - vii. Prolactin for men with reduced sperm counts, galactorrhea, or pituitary tumors;
  - viii. Sex hormone binding globulin (SHGB) for men with signs and symptoms of hypogonadism and low normal testosterone levels. (SHGB is not indicated in the routine evaluation of male infertility);
  - ix. Thyroid stimulating hormone (TSH) for men with symptoms of thyroid disease;
- d. Semen analysis - Semen analysis (volume, pH, liquefaction time, sperm concentration, total sperm number, motility (forward progression), motile sperm per ejaculate, vitality, round cell differentiation (white cells versus germinal), morphology, viscosity, agglutination) is considered medically necessary for the evaluation of infertility in men. Because of the marked inherent variability of semen analyses, an abnormal

result should be confirmed by at least one additional sample collected one or more weeks after the first sample;

- i. For men with abnormal semen analysis exposed to gonadotoxins, up to 4 semen analyses are considered medically necessary;
  - ii. For men with a normal initial semen analysis, a repeat semen analysis is considered medically necessary if there is no pregnancy 4 months after the initial normal semen analysis;
  - iii. If the result of the first semen analysis is abnormal and the man has not been exposed to gonadotoxins, up to 2 repeat confirmatory tests may be considered medically necessary;
- e. Vasography;
- f. Semen leukocyte analysis (e.g., Endtz test, immunohistochemical staining);
- g. Seminal fructose; **Note:** Seminal alpha-glucosidase, zinc, citric acid, and acid phosphatase are considered experimental and investigational.
- h. Blood test for cytogenetic analysis (karyotype and FISH) in men with severe deficits of semen quality or azoospermia (for consideration of ICSI);
- i. Cystic fibrosis mutation testing in men with congenital absence of vas deferens;
- j. Y chromosome microdeletion analysis in men with severe deficits of semen quality or azoospermia (for consideration of ICSI); **Note:** Y chromosome microdeletion analysis is not routinely indicated before ICSI, and is subject to medical necessity review.
- k. Post-coital test (PCT) (Simms-Huhner test) of cervical mucus;
- l. Sperm penetration assay (zona-free hamster egg penetration test);
- m. Karyotyping for persons with recurrent pregnancy loss (defined as 2 or more consecutive spontaneous abortions) (See [CPB 0348 - Recurrent Pregnancy Loss \(0348.html\)](#)) and for men with severe deficits in semen

- quality or nonobstructive azoospermia (for consideration of ICSI);
- n. Testing for viral status (HIV, hepatitis B, hepatitis C);
- o. Genetic testing of CFTR mutations for a man and his female partner if the man has congenital absence of the vas deferens (CAVD);
3. Diagnostic procedures
- a. CT or MR imaging of sella turcica if prolactin is elevated;
- b. Scrotal exploration;
- c. Scrotal (testicular) ultrasound (See [CPB 0532 - Scrotal Ultrasonography](https://www.aetna.com/cpb/medical/data/500_599/0532.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/500\\_599/0532.html](https://www.aetna.com/cpb/medical/data/500_599/0532.html)));
- d. Testicular biopsy;
- e. Transrectal ultrasound (See [CPB 0001 - Transrectal Ultrasound](https://www.aetna.com/cpb/medical/data/1_99/0001.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/1\\_99/0001.html](https://www.aetna.com/cpb/medical/data/1_99/0001.html)));
- f. Vasography;
- g. Venography;

**Note:** Fine needle aspiration (“mapping”) of testes, and microdissection of the zona are considered experimental and investigational because their efficacy has not been established.

#### 4. Treatments

- a. Endocrine Management
- i. Androgens (testosterone) for persons with documented androgen deficiency;
- ii. Anti-estrogens (tamoxifen (Nolvadex)) for men with elevated estrogen levels;
- iii. Clomiphene (Clomid, Serophene);
- iv. Corticosteroids (e.g., dexamethasone, prednisone);
- v. Prolactin inhibitors (bromocriptine (Parlodel), cabergoline (Dostinex)) for persons with

hyperprolactinemia;

- vi. Thyroid hormone replacement for men with thyroid deficiency;

b. Injectable Endocrine Management

- i. Gonadotropin releasing hormone analogs and antagonists - for gonadotropin-releasing hormone analogs and antagonists (GnRH; luteinizing hormone releasing hormone (LHRH)) see

[CPB 0501 - Gonadotropin-Releasing Hormone Analogs and Antagonists \(/web/20230401084153/https://www.aetna.com/cpb/medical/data/500\\_599/0501.html\)](https://www.aetna.com/cpb/medical/data/500_599/0501.html)

;

ii. Gonadotropins

- a. Human chorionic gonadotropin (hCG) (e.g., Novarel, Pregnyl, Ovidrel, generic)

- i. Criteria for Initial Approval:

Aetna considers hCG medically necessary for the following indications when criteria are met:

- a. Hypogonadotropic hypogonadism - for treatment of hypogonadotropic hypogonadism in members who meet *both* of the following criteria:

- i. Low pretreatment testosterone levels;  
*and*
        - ii. Low or low-normal follicle stimulating hormone (FSH) or luteinizing hormone (LH) levels.

- b. Prepubertal cryptorchidism treatment.

Aetna considers all other indications as experimental and investigational (for additional information, see Experimental and

Investigational and Background sections.)

ii. Continuation of Therapy:

Aetna considers continuation of hCG therapy medically necessary for all members (including new members) requesting reauthorization who meet all initial authorization criteria.

b. Follitropins (e.g., follitropin alfa [Gonal-f]; follitropin beta [Follistim AQ])

i. Criteria for Initial Approval:

Aetna considers follitropins medically necessary for treatment of hypogonadotropic hypogonadism in members who meet *both* of the following criteria:

- a. Low pretreatment testosterone levels; *and*
- b. Low or low-normal follicle stimulating hormone (FSH) or luteinizing hormone (LH) levels.

ii. Continuation of Therapy:

Aetna considers continuation of follitropins therapy medically necessary for all members (including new members) requesting reauthorization who meet all initial authorization criteria.

**Note:** Many plans that otherwise cover infertility treatments exclude coverage for infertility injectable medications. Please check benefit plan descriptions.

c. Antibiotics for men with an identified infection; **Note:**

Intra-prostatic antibiotic injection is considered experimental and investigational;

d. Varicocelectomy (spermatic vein ligation) - see [CPB 0413 - Varicocele: Selected Treatments](#)



([/web/20230401084153/https://www.aetna.com/cpb/medical/data/400\\_499/0413.html](https://www.aetna.com/cpb/medical/data/400_499/0413.html));

- e. Spermatocelectomy and hydrocelectomy;
- f. Surgical repair of vas deferens: vasovasostomy; **Note:**  
Most plans exclude coverage for reversal of sterilization procedures. This would include vasectomy. Please check benefit plan descriptions for details.
- g. Surgical correction of epididymal blockage for men with obstructive azoospermia:
  - i. Epididymectomy;
  - ii. Epididymovasostomy;
  - iii. Excision of epididymal tumors and cysts;
  - iv. Epididymostomy;
- h. Transurethral resection of ejaculatory ducts (TURED) for obstruction of ejaculatory ducts;
- i. Orchiopexy;
- j. Alpha sympathomimetic agents for retrograde ejaculation (e.g., phenylephrine, imipramine);
- k. Hepatitis B vaccination of partners of people with hepatitis B;
- l. Impotence treatments - see [CPB 0007 - Erectile Dysfunction](https://www.aetna.com/cpb/medical/data/1_99/0007.html)  
([/web/20230401084153/https://www.aetna.com/cpb/medical/data/1\\_99/0007.html](https://www.aetna.com/cpb/medical/data/1_99/0007.html)).

**Note:** Under most Aetna benefit plans, self-administered prescription medications are covered under the pharmacy benefit. Please check benefit plan descriptions.

#### D. *Artificial Insemination*

- 1. Aetna considers artificial insemination (intra-cervical insemination or intra-uterine insemination [IUI]) to be medically necessary for treatment of infertility for any of the following:
  - a. infertile couples with mild male-factor fertility problems;
  - b. unexplained infertility problems;

- c. minimal to mild endometriosis;
  - d. medically refractory erectile dysfunction or vaginismus preventing intercourse;
  - e. couples where the man is HIV positive and undergoing sperm washing;
  - f. couples undergoing menotropin ovarian stimulation; or
  - g. clomiphene-citrate-stimulated artificial insemination (intra-cervical insemination or IUI) medically necessary for infertile women with WHO Group II ovulation disorders such as polycystic ovarian syndrome who ovulate with clomiphene citrate but have not become pregnant after ovulation induction with clomiphene.
2. **Note:** For purposes of this policy, mild male-factor infertility is defined as when 2 or more semen analyses, measured at least two weeks apart, have 1 or more variables below the 5th percentile (NICE, 2013).
3. Aetna considers electroejaculation medically necessary DME to overcome total anejaculation secondary to neurologic impairment, which most commonly occurs among members with the following conditions:
- a. Diabetic neuropathy;
  - b. Prior retroperitoneal surgery (most commonly retroperitoneal lymphadenectomy as a treatment of testicular cancer);
  - c. Spinal cord injury.
4. Donor insemination is considered medically necessary for the following indications:
- a. Non-obstructive azoospermia;
  - b. Obstructive azoospermia;
  - c. Severe deficits in semen quality in couples who do not wish to undergo intracytoplasmic sperm injection (ICSI);
  - d. Severe rhesus isoimmunization;
  - e. Where there is a high risk of transmitting a genetic disorder in the male partner to the offspring;\*

- f. Where there is a high risk of transmitting an infectious disease (such as HIV) to the partner or offspring.\*

**Notes:**

Many Aetna plans that otherwise cover infertility services exclude coverage of fees associated with donor insemination (including semen donor recruitment, selection and screening, and cryostorage of sperm). In addition, cryopreservation of semen not covered as it is not considered treatment of disease. Please check benefit plan descriptions for details.

\* Some plans limit coverage of donor insemination to couples who are infertile. Under these plans, donor insemination would not be covered for these indications (infectious disease in male partner, high risk of transmitting a genetic disorder) as these do not meet the contractual definition of infertility. Please check benefit plan descriptions.

**Note:** Some Aetna benefit plans may exclude coverage of artificial insemination (AI). For Aetna benefit plans that cover artificial insemination, coverage is typically limited to six (6) cycles per lifetime. Please check benefit plan descriptions.

E. *Advanced Reproductive Technology*

Aetna considers the following Advanced Reproductive Technologies (ART) procedures medically necessary for infertility in persons who meet *any* of the following criteria:

1. Women who have failed to conceive after a trial of ovarian stimulation:
  - a. For women 37 years of age or younger, three cycles of ovarian stimulation (with or without intrauterine insemination); *or*
  - b. For women 38 years of age or older, no trial of ovarian stimulation is required; *or*

2. Persons for whom natural or artificial insemination would not be expected to be effective and ART would be expected to be the only effective treatment, including:

- a. Men with azoospermia or severe deficits in semen quality or quantity (see [Appendix](#)); or
- b. Women with tubal factor infertility:
  - i. Bilateral tubal disease (e.g., salpingitis isthmica nodosum, tubal obstruction, absence, or hydrosalpinges).
  - ii. Endometriosis stage 3 or 4 (see [Appendix](#)).
  - iii. Failure to conceive after pelvic surgery with restoration of normal pelvic anatomy (e.g., myomectomy of cavity-obscuring myomata, resection of intrauterine adhesions or uterine septum, or surgical reconstruction of tubal disease):
    - a. After trying to conceive for 6 months if less than 40 years of age;
    - b. After trying to conceive for 3 months if 40 years of age or older.
  - iv. Ectopic pregnancy occurring during infertility treatment.
  - v. Unilateral hydrosalpinx with failure to conceive:
    - a. After trying to conceive for 12 months if less than 40 years of age;
    - b. After trying to conceive for 6 months if 40 years of age or older.
- c. Inadvertent ovarian hyperstimulation (estradiol level was greater than 1,000 pg/ml plus greater than 3 follicles greater than 16 mm or 4 to 8 follicles greater than 14 mm or a larger number of smaller follicles) during preparation for a planned stimulated cycle in women less than 38 years of age.

- d. Women who have had a hysterectomy, or who have a medical contraindication to pregnancy such as severe cardiac disease, or have a medical condition that requires the mother to ingest a fetotoxic agent. Note: Some plans limit and/or exclude coverage for gestational surrogacy; please check benefit plan descriptions.

**Note:** Coverage is limited to plans with an ART benefit; please check benefit plan descriptions).

**Note on coverage of ART for preimplantation genetic**

**diagnosis (PGD):** The procedure to obtain the cell sample for PGD (i.e., the embryo biopsy) is covered when medical necessity criteria for PGD are met as set forth in [CPB 0358 - Invasive Prenatal Diagnosis of Genetic Diseases \(0358.html\)](#)

. However, under plans that limit coverage of ART to persons who are infertile, the in-vitro fertilization (IVF) procedure (i.e., the procedures and services required to create the embryos to be tested and the transfer of the appropriate embryos back to the uterus after testing) is covered only for persons with ART benefits who are infertile (please check benefit plan descriptions) and meet medical necessity criteria for ART.

3. IVF with embryo transfer is considered medically necessary when criteria for ART are met. IVF with embryo transfer includes:

- a. Embryo transfer (transcervical transfer back to the donor) (including cryopreserved embryo transfer);
- b. Frozen embryo transfer (FET); (**Note:** It may be considered medically necessary to freeze embryos not transferred during a stimulated IVF treatment cycle, and to transfer the embryos before the next stimulated treatment cycle because this will minimize ovulation induction and egg collection, both of which carry risks for the woman and use more resources. Before proceeding to a fresh ART cycle, previously frozen oocytes must be used (i.e. fertilized and transferred).

Similarly, Before proceeding to the next fresh ART cycle, FET using cryopreserved embryos must be used if there are reasonable quality (grade B or its equivalent) cryopreserved embryo(s) available.

- c. Oocyte (egg) insemination in laboratory dish;
- d. Oocyte (egg) retrieval via laparoscope or transvaginal needle aspiration of follicles;
- e. Sperm preparation and capacitation;
- f. Intra-cytoplasmic sperm injection (ICSI) is medically necessary for the following:
  - i. azoospermia or oligospermia (obstructive or non-obstructive),
  - ii. severe deficits in semen quality or quantity (see [Appendix](#)),
  - iii. to fertilize frozen oocytes for in vitro fertilization,
  - iv. persons facing iatrogenic infertility due to cancer chemotherapy, cancer radiotherapy, or surgery for trauma; *or*
  - v. for couples where a previous IVF treatment cycle has resulted in failed or poor (see [Appendix](#)) fertilization;

**Note:** ICSI is considered not medically necessary in men whose abnormal sperm quality or quantity had been rectified by varicocelelectomy. (For use of ICSI in preimplantation genetic diagnosis, see [CPB 0358 - Invasive Prenatal Diagnosis of Genetic Diseases \(0358.html\)](#)).
- g. Assisted hatching is considered medically necessary when the plan in the cycle is to transfer the embryos into the uterus and the member meets any of the following criteria:
  - i. Age is 38 years or older; *or*
  - ii. Multiple (2 or more) failed embryo transfer attempts; *or*
  - iii. Thickened zona pellucida.

**Note:** Assisted hatching is a process to assist in the implantation of the embryo; unless the cycle involves that transfer of the embryo assisted hatching is considered not medically necessary.

**Note on IVF cycles for embryo banking:** IVF cycles for the sole purpose of embryo banking (where none of the embryos that are suitable for transfer are used in the current cycle in which they are created, but are frozen for use in a future cycle) is not considered treatment of disease and is not covered.

**Note on oocytes used in ART cycles:** IVF cycles using either fresh or previously frozen oocytes are considered medically necessary when the ART cycle is considered medically necessary.

4. Gamete intra-fallopian transfer (GIFT) is considered medically necessary as an alternative to IVF for women with female factor infertility. GIFT includes:

- a. Immediate loading of the eggs into a transfer catheter with sperm and insertion into the member's fallopian tube via the same laparoscope (the member must have at least 1 patent fallopian tube for this method to be an effective treatment for infertility)
- b. Oocyte (egg) retrieval via laparoscope.

GIFT is considered experimental and investigational for person with male factor infertility or unexplained infertility problems because there is insufficient evidence to recommend GIFT over IVF for these indications.

5. Zygote intra-fallopian transfer (ZIFT), tubal embryo transfer (TET), pronuclear stage tubal embryo transfer (PROUST) is considered medically necessary as an alternative to IVF for women with female factor infertility.

ZIFT is considered experimental and investigational for persons with male factor infertility or unexplained infertility problems because there is insufficient evidence to recommend ZIFT over IVF for these indications.

6. Specialized sperm retrieval techniques (including vasal sperm aspiration, microsurgical epididymal sperm aspiration (MESA), percutaneous epididymal sperm aspiration (PESA), electroejaculation, testicular sperm aspiration (TESA), microsurgical testicular sperm extraction (TESE), seminal vesicle sperm aspiration, and sperm recovery from bladder or urine for retrograde ejaculation) is considered medically necessary to overcome anejaculation or azoospermia.

**Note:** Most plans exclude coverage of infertility services for persons who have undergone sterilization. This would include sperm retrieval for men who have undergone vasectomy. Please check benefit plan descriptions for details.

7. Oocyte donation is considered medically necessary for managing infertility problems associated with the following conditions, when the infertile member is the intended recipient of the resulting embryos:

- a. Bilateral oophorectomy;
- b. Gonadal dysgenesis including Turner syndrome;
- c. High-risk of transmitting a genetic disorder from the female partner to the offspring;
- d. IVF treatment failure
- e. Ovarian failure following chemotherapy or radiotherapy;  
*or*
- f. Premature ovarian failure (failure of ovulation in woman younger than 40 years of age) (considered medically necessary until the woman with POF is 45 years of age).

**Note:** Many Aetna plans that otherwise cover infertility services exclude coverage of fees associated with oocyte donation, including recruitment and selection of donors, ovarian stimulation of donors, collection of oocytes from



donors, and screening and storage of donor oocytes.

Please check benefit plan descriptions for details. Under plans with benefits for IVF that have this exclusion, medically necessary IVF services are covered only once an embryo is created from the donor egg.

8. The IVF procedure to cryopreserve mature gametes (oocytes or sperm) or embryos is considered medically necessary for use in persons facing iatrogenic infertility due to chemotherapy, pelvic radiotherapy, other gonadotoxic therapies, or ovary or testicle removal for treatment of disease.

Routine use of gamete cryopreservation in lieu of embryo cryopreservation, gamete cryopreservation to circumvent reproductive aging in healthy persons, cryopreservation of immature gametes, and laser-assisted necrotic blastomere removal from cryopreserved embryos are considered experimental and investigational.

**Note:** Some Aetna plans have a specific contractual exclusion of coverage of any charges associated with embryo cryopreservation or storage of cryopreserved embryos. Please check benefit plan descriptions. In addition, cryopreservation of embryos and gametes (other than short-term cryopreservation of embryos that are necessary for contemporaneous use in infertile persons currently under active fertility treatment, or use of cryopreserved embryos or mature gametes in persons facing infertility due to chemotherapy or other gonadotoxic therapies or gonad removal) is not considered treatment of disease and is not covered.

9. Cryopreservation of sperm is considered medically necessary in men facing iatrogenic infertility due to chemotherapy, pelvic radiotherapy, other gonadotoxic therapies, or testicular removal for treatment of disease.

Sperm cryopreservation to circumvent reproductive aging in healthy men is considered experimental and investigational.

**Note:** Some Aetna plans have a specific contractual exclusion of coverage of any charges associated with sperm cryopreservation or storage. Please check benefit plan descriptions. In addition, cryopreservation of sperm (other than cryopreserved sperm in men facing infertility due to chemotherapy or other gonadotoxic therapies or gonad removal) is not considered treatment of disease and is not covered.

**Note:** A cycle of ART defined in the CPB may be any of the following: IVF (with fresh embryos), IVF/frozen embryo transfer, GIFT or ZIFT.

**Note on elective single embryo transfer:** In order to reduce the number of high-order multiple pregnancies, current guidelines from the American Society for Reproductive Medicine (ASRM, 2009) recommend elective single embryo transfer for women under the age of 35 who have no prior IVF cycles or who have had a previous IVF cycle that was successful in producing a pregnancy (i.e., documentation of fetal heartbeat) and who have excess embryos of sufficient quality to warrant cryopreservation. For women who meet these criteria who elect transfer of a single fresh embryo, Aetna will consider transfer of 1 cryopreserved embryo immediately subsequent to the fresh embryo transfer as part of the same IVF cycle, under plans that limit the number of IVF cycles that are covered. Please check benefit plan descriptions for details.

## II. Experimental and Investigational

The following are considered experimental and investigational for infertility:

- A. Acupuncture (see [CPB 0135 - Acupuncture](https://www.aetna.com/cpb/medical/data/100_199/0135.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/100\\_199/0135.html](https://www.aetna.com/cpb/medical/data/100_199/0135.html)))
- B. Bariatric surgery (see [CPB 0157 - Obesity Surgery](https://www.aetna.com/cpb/medical/data/100_199/0157.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/100\\_199/0157.html](https://www.aetna.com/cpb/medical/data/100_199/0157.html)));

- C. Dehydroepiandrosterone (DHEA)
- D. Direct intra-peritoneal insemination, fallopian tube sperm transfusion, intra-follicular insemination, and the use of sperm precursors (i.e., round or elongated spermatid nuclei, immature sperm)
- E. Drainage of ovarian cyst
- F. DuoStim IVF protocol
- G. Early Embryo Viability Assessment (Eeva) test
- H. EmbryoGlue
  - I. Evaluation of CYP1A1 rs4646903 T > C genetic variations for risk of male infertility
  - J. Evaluation of *FAS/FASL* genetic variations for risk of male infertility
- K. Evaluation of telomere length
- L. Fine needle aspiration ("mapping") of testes
- M. FSH manipulation of women with elevated FSH levels (an elevated FSH level is a marker of reduced ovarian reserve, as occurs with advancing age. Elevated FSH-related (i.e., age-related) infertility has not been proven to be affected by interventions to reduce FSH levels)
- N. Germ cell transplantation or cultured testicular stem cells
- O. Growth hormone: there is inadequate evidence that the use of adjuvant growth hormone treatment during ovulation induction improves pregnancy rates. See [CPB 0170 - Growth Hormone \(GH\) and Growth Hormone Antagonists \(/web/20230401084153/https://www.aetna.com/cpb/medical/data/100\\_199/0170.html\)](https://www.aetna.com/cpb/medical/data/100_199/0170.html).
- P. GIFT for person with male factor infertility or unexplained infertility problems
- Q. Human chorionic gonadotropin (hCG) for in vitro fertilization with frozen-thawed embryos
- R. Human chorionic gonadotropin (hCG) and follitropins for idiopathic male infertility (except for the medically necessary indications outlined above), idiopathic microphallus and all other indications in men
- S. Hyperbaric oxygen therapy for the treatment of male infertility
- T. Intralipid infusion for the treatment of female infertility
- U. Intrauterine injection/infusion of platelet rich plasma for the treatment of female infertility

- V. Intravenous immunoglobulins for treatment of infertility  
(See [CPB 0348 - Recurrent Pregnancy Loss \(0348.html\)](#)); and [CPB 0206 - Parenteral Immunoglobulins \(/web/20230401084153/https://www.aetna.com/cpb/medical/data/200\\_299/0206.html\)](#))
- W. In-vitro maturation of oocytes
- X. Leukocyte immunization (immunizing the female partner with the male partner's leukocytes (see [CPB 0348 - Recurrent Pregnancy Loss \(0348.html\)](#)))
- Y. Menotropins for Injection (Menopur) for treatment of male infertility
- Z. Parenteral administration of lipids
- AA. Partial zonal dissection (PZD)
- AB. Preimplantation genetic testing for aneuploidy (PGT-A) (formerly called preimplantation genetic screening (PGS)) for IVF optimization (see [CPB 0358 - Invasive Prenatal Diagnosis of Genetic Diseases \(0358.html\)](#))
- AC. Stem cell therapy
- AD. Subzonal sperm insertion (SUZI)
- AE. Uterine transplant
- AF. Vaginal sildenafil
- AG. Vasodilators for women undergoing fertility treatment
- AH. ZIFT for persons with male factor infertility or unexplained infertility problems
- AI. The following sperm function tests are considered experimental and investigational:
  - 1. Acrosome reaction test
  - 2. Comet assay
  - 3. Computer-assisted sperm analysis (CASA)/computer-assisted sperm motion analysis
  - 4. Hemizona assay
  - 5. Hyaluronan binding assay
  - 6. Hypoosmotic swelling test
  - 7. In vitro testing of sperm penetration
  - 8. Reactive oxygen species (ROS) test
  - 9. Sperm chromatin assay
  - 10. Sperm DNA condensation test
  - 11. Sperm DNA fragmentation assay

12. Sperm nucleus maturation

13. TUNEL assay

AJ. The following laboratory studies are considered experimental and investigational for infertility:

1. Anti-CarP (anti-carbamylated proteins) panel

2. Antinuclear antibodies

3. Antiovarian antibodies

4. Antiphospholipid antibodies

5. Antiphosphatidic acid antibodies

6. Antiphosphatidylethanolamine antibodies

7. Antiphosphatidylglycerol antibodies

8. Antiphosphatidylinositol antibodies

9. Antiphosphatidylserine antibodies

10. Antiprothrombin antibodies (see [CPB 0662 -](#)

[Antiprothrombin Antibody Testing](#)

[\(/web/20230401084153/https://www.aetna.com/cpb/medical/data/600\\_699/0662.html\)\)](#)

11. Antithrombin III (ATIII) activity

12. Antithrombin III (ATIII) antigen

13. Antithyroglobulin antibodies

14. Embryotoxicity assay (see [CPB 0348 - Recurrent Pregnancy Loss \(0348.html\)](#))

15. Endometrial receptivity testing (e.g., endometrial receptivity analysis (Igenomix), endometrial receptivity array (ERA), integrin testing, beta-3 integrin test)

16. Evaluation of telomere length

17. Factor V Leiden coagulation

18. Factor V Leiden mutation (see [CPB 0140 - Genetic Testing \(/web/20230401084153/https://www.aetna.com/cpb/medical/data/100\\_199/0140.html\)\)](#))

19. HLA genotyping (A, B, C, DR, DQ)

20. Homocysteine (see [CPB 0763 - Homocysteine Testing \(/web/20230401084153/https://www.aetna.com/cpb/medical/data/700\\_799/0763.html\)\)](#))

21. Methylenetetrahydrofolate reductase (MTHFR)

22. Oxidative Stress Adduct Test (OSA)

23. Plasminogen Activator Inhibitor-I activity

24. Plasminogen Activator Inhibitor-I (PAI-1) antigen

25. Protein C activity
26. Protein C antigen
27. Protein S activity
28. Protein S antigen (free or total)
29. Prothrombin (Factor II) mutation (see [CPB 0140 - Genetic Testing](https://www.aetna.com/cpb/medical/data/100_199/0140.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/100\\_199/0140.html](https://www.aetna.com/cpb/medical/data/100_199/0140.html)))
30. Uterine and endometrial receptivity testing (Endometrial function test (EFT) (cyclin E and p27) and E-tegrity)
31. Measurement of natural killer (NK) cell activity
32. Reproductive immunophenotyping
33. Serum inhibin B measurement (value in assessing ovarian reserve is uncertain)
34. Th1 (T Helper 1) and Th2 (T Helper 2) intracellular cytokine assay (Th1/Th2 ratio)
35. uBiome SmartJane screen (see [CPB 0650 - Polymerase Chain Reaction Testing: Selected Indications](https://www.aetna.com/cpb/medical/data/600_699/0650.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/600\\_699/0650.html](https://www.aetna.com/cpb/medical/data/600_699/0650.html)))
36. Vaginal microbiota.

### III. Related Policies

- [CPB 0001 - Transrectal Ultrasound](https://www.aetna.com/cpb/medical/data/1_99/0001.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/1\\_99/0001.html](https://www.aetna.com/cpb/medical/data/1_99/0001.html))
- [CPB 0007 - Erectile Dysfunction](https://www.aetna.com/cpb/medical/data/1_99/0007.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/1\\_99/0007.html](https://www.aetna.com/cpb/medical/data/1_99/0007.html))
- [CPB 0020 - Injectable Medications](https://www.aetna.com/cpb/medical/data/1_99/0020.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/1\\_99/0020.html](https://www.aetna.com/cpb/medical/data/1_99/0020.html))
- [CPB 0135 - Acupuncture](https://www.aetna.com/cpb/medical/data/100_199/0135.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/100\\_199/0135.html](https://www.aetna.com/cpb/medical/data/100_199/0135.html))
- [CPB 0140 - Genetic Testing](https://www.aetna.com/cpb/medical/data/100_199/0140.html) ([/web/20230401084153/https://www.aetna.com/cpb/medical/data/100\\_199/0140.html](https://www.aetna.com/cpb/medical/data/100_199/0140.html))

- [CPB 0157 - Obesity Surgery](https://www.aetna.com/cpb/medical/data/100_199/0157.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/100\_199/0157.html).
- [CPB 0170 - Growth Hormone \(GH\) and Growth Hormone Antagonists](https://www.aetna.com/cpb/medical/data/100_199/0170.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/100\_199/0170.html).
- [CPB 0189 - Genetic Counseling](https://www.aetna.com/cpb/medical/data/100_199/0189.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/100\_199/0189.html).
- [CPB 0206 - Parenteral Immunoglobulins](https://www.aetna.com/cpb/medical/data/200_299/0206.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/200\_299/0206.html).
- [CPB 0323 - Preconceptional Sex Selection Techniques \(0323.html\)](https://www.aetna.com/cpb/medical/data/0323.html)
- [CPB 0347 - Transcervical Balloon Tuboplasty \(0347.html\)](https://www.aetna.com/cpb/medical/data/0347.html)
- [CPB 0348 - Recurrent Pregnancy Loss \(0348.html\)](https://www.aetna.com/cpb/medical/data/0348.html)
- [CPB 0358 - Invasive Prenatal Diagnosis of Genetic Diseases \(0358.html\)](https://www.aetna.com/cpb/medical/data/0358.html)
- [CPB 0413 - Varicocele: Selected Treatments](https://www.aetna.com/cpb/medical/data/400_499/0413.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/400\_499/0413.html).
- [CPB 0433 - Chlamydia Trachomatis - Screening and Diagnosis](https://www.aetna.com/cpb/medical/data/400_499/0433.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/400\_499/0433.html).
- [CPB 0501 - Gonadotropin-Releasing Hormone Analogs and Antagonists](https://www.aetna.com/cpb/medical/data/500_599/0501.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/500\_599/0501.html).
- [CPB 0510 - Progestins](https://www.aetna.com/cpb/medical/data/500_599/0510.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/500\_599/0510.html).
- [CPB 0532 - Scrotal Ultrasonography](https://www.aetna.com/cpb/medical/data/500_599/0532.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/500\_599/0532.html).
- [CPB 0650 - Polymerase Chain Reaction Testing: Selected Indications](https://www.aetna.com/cpb/medical/data/600_699/0650.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/600\_699/0650.html).

- [CPB 0662 - Antiprothrombin Antibody Testing](https://www.aetna.com/cpb/medical/data/600_699/0662.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/600\_699/0662.html).
- [CPB 0763 - Homocysteine Testing](https://www.aetna.com/cpb/medical/data/700_799/0763.html)  
(/web/20230401084153/https://www.aetna.com/cpb/medical/data/700\_799/0763.html).

## Applicable CPT / HCPCS / ICD-10 Codes

*Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+".*

Code	Code Description
CPT codes covered if selection criteria are met:	
0167U	Gonadotropin, chorionic (hCG), immunoassay with direct optical observation, blood
49203	Excision or destruction, open, intra-abdominal tumors, cysts or endometriomas, 1 or more peritoneal, mesenteric, or retroperitoneal primary or secondary tumors; largest tumor 5 cm diameter or less
49204	largest tumor 5.1 - 10.0 cm diameter
49205	largest tumor greater than 10.0 cm diameter
49320	Laparoscopy, abdomen, peritoneum, and omentum, diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)
49321	Laparoscopy, surgical; with biopsy (single or multiple)
49322	with aspiration of cavity or cyst (eg, ovarian cyst) (single or multiple)
52402	Cystourethroscopy with transurethral resection or incision of ejaculatory ducts
54500	Biopsy of testis, needle (separate procedure)
54505	Biopsy of testis, incisional (separate procedure)



# **EXHIBIT B**



**Secretary of State**  
**Statement of Information**  
 (Limited Liability Company)

**LLC-12**

**22-A17555**

**FILED**

In the office of the Secretary of State  
 of the State of California

**JAN 11, 2022**

This Space For Office Use Only

**IMPORTANT** — This form can be filed online at  
[bizfile.sos.ca.gov](http://bizfile.sos.ca.gov).

[Read instructions](#) before completing this form.

**Filing Fee - \$20.00**

**Copy Fees** - First page \$1.00; each attachment page \$0.50;  
 Certification Fee - \$5.00 plus copy fees

**1. Limited Liability Company Name** (Enter the **exact** name of the LLC. If you registered in California using an alternate name, [see instructions](#).)

ENCORE GROUP (USA) LLC

**2. 12-Digit Secretary of State Entity Number**

201803610056

**3. State, Foreign Country or Place of Organization** (only if formed outside of California)

DELAWARE

**4. Business Addresses**

a. Street Address of Principal Office - Do not list a P.O. Box	City (no abbreviations)	State	Zip Code
5100 N River Rd, Ste 300	Schiller Park	IL	60176
b. Mailing Address of LLC, if different than item 4a	City (no abbreviations)	State	Zip Code
5100 N River Rd, Ste 300	Schiller Park	IL	60176
c. Street Address of <b>California</b> Office, if Item 4a is not in California Do not list a P.O. Box	City (no abbreviations)	State	Zip Code
		<b>CA</b>	

**5. Manager(s) or Member(s)**

If no managers have been appointed or elected, provide the name and address of each member. At least one name and address must be listed. If the manager/member is an individual, complete Items 5a and 5c (leave Item 5b blank). If the manager/member is an additional managers/members, enter the names(s) and address(es) on [Form LLC-12A](#).

a. First Name, if an individual - Do not complete Item 5b	Middle Name	Last Name	Suffix
Benjamin		Erwin	
b. Entity Name - Do not complete Item 5a			
c. Address	City (no abbreviations)	State	Zip Code
5100 N River Rd, Ste 300	Schiller Park	IL	60176

**6. Service of Process** (Must provide either Individual **OR** Corporation.)

**INDIVIDUAL** – Complete Items 6a and 6b only. Must include agent’s full name and California street address.

a. California Agent’s First Name (if agent is <b>not</b> a corporation)	Middle Name	Last Name	Suffix
b. Street Address (if agent is <b>not</b> a corporation) - <b>Do not enter a P.O. Box</b>	City (no abbreviations)	State <b>CA</b>	Zip Code

**CORPORATION** – Complete Item 6c only. Only include the name of the registered agent Corporation.

c. California Registered Corporate Agent’s Name (if agent is a corporation) – Do not complete Item 6a or 6b C T CORPORATION SYSTEM (C0168406)
--

**7. Type of Business**

Describe the type of business or services of the Limited Liability Company Audio Visual Goods and Services
---

**8. Chief Executive Officer, if elected or appointed**

a. First Name Benjamin	Middle Name	Last Name Erwin	Suffix
b. Address 5100 N River Rd, Ste 300	City (no abbreviations) Schiller Park	State IL	Zip Code 60176

**9. Labor Judgment**

Does a Manager or Member have an outstanding final judgment issued by the Division of Labor Standards Enforcement or a court of law, for which no appeal therefrom is pending, for the violation of any wage order or provision of the Labor Code?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
--	---

**10.** By signing, I affirm under penalty of perjury that the information herein is true and correct and that I am authorized by California law to sign.

01/11/2022      Janalin Melendez      Assistant Secretary  
 \_\_\_\_\_  
 Date      Type or Print Name      Title      Signature